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Abstract 
 
Catherine E. Steding 
 
The Role of Interleukin-12 on Modulating Myeloid-Derived Suppressor Cells  
More than 200,000 American women are diagnosed with breast cancer each year. 
Although therapies effective in treating metastatic breast cancer currently exist, each 
year approximately 40,000 women die from this disease. Current evidence indicates that 
anti-cancer immune responses can be induced by vaccination in situ to the growth of 
metastasis and protect patients from the tumor recurrence. However, induction of anti-
cancer immune responses may be limited in their efficacy due to immune suppression 
mechanisms induced by the developing cancer. Myeloid-derived suppressor cells are 
one population of immune regulators comprised of immature cells of myeloid origin with 
important roles in blocking immune activation and promoting tumor progression. 
Elimination or maturation of these cells has been found to promote enhanced anti-tumor 
effects and improve overall survival. This thesis identifies a new role for interleukin-12 as 
a modulator of myeloid-derived suppressor cell activity. Interleukin-12 was found to 
promote up-regulation of cell maturation markers on the surface of myeloid-derived 
suppressor cells with an accompanying decrease in factors responsible for conferring 
suppressive activity such as nitric oxide synthase 2 and arginase I. The alterations in 
myeloid-derived suppressor cells were observed following both in vitro and in vivo 
treatment with interleukin-12. Further analysis of the anti-tumor efficacy of interleukin-12 
revealed that at least part of its suppression of tumor growth can be linked to reductions 
in myeloid-derived suppressor cell populations in the tumor microenvironment and an 
influx of active CD8+ T cells into the tumor microenvironment. The findings outlined in 
this thesis show that interleukin-12 alters the suppressive function of myeloid-derived 
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suppressor cells leading to significant immune infiltration and activation resulting in 
increased overall survival and a reduction in metastasis. 
 
Chinghai Kao, Ph.D., Chair 
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Introduction 
 
Breast Cancer and Clinical Significance 
Out of every 1000 women as many as 125 of them will develop breast cancer in their 
lifetime. More than 200,000 American women are diagnosed with breast cancer each 
year. The chance of a woman diagnosed with breast cancer succumbing to the disease 
is 1 in 33 (1). Although the death rates for breast cancer have exhibited a steady decline, 
predominantly due to improvements in early screening and detection, it remains one of 
the most diagnosed cancers in women worldwide and the second leading cause of 
cancer-related death in American women (2). Understanding the nature of breast cancer 
in terms of both growth and progression is crucial to combating this deadly disease.  
 
Breast cancer is a complex and heterogeneous cancer of the tissues in the breast. As a 
heterogeneous disease, different morphologies, molecular profiles, and responses to 
treatments exist. A classification system based on the differences in gene expression 
profiles reinforces what was found from pathological analysis or tumors and has led to a 
better definition of individual breast cancers. The classification system has even 
generated a better understanding of which treatment protocol has the most potential for 
optimal clinical outcomes for a given type of breast cancer. Better classification of breast 
cancers also helps in defining the overall prognosis for an individual patient beyond 
those provided by traditional assessments of tumor grade.  
 
There are several types of breast cancer based on tissue type. The majority of breast 
cancers are ductal in origin (3). Ductal carcinoma in situ is a cancer that remains 
confined to the ducts of the breast. In addition to cancers of the ducts of the breast are 
cancers of the lobules of the breast. Lobular carcinoma in situ despite its name is not a 
cancer but does define an increased risk for developing cancer. In addition to defining 
the type of cancer based on tissue type, the next stage in pathologic classification 
defines whether the cancer has remained within the confines of the individual tissue or 
has spread to adjacent breast tissue and become invasive carcinoma (3). Invasive 
ductal carcinoma is a cancer that is initiated in the ducts but that has spread through the 
wall into the breast tissue. Invasive lobular carcinoma is a cancer that starts in the 
lobules of the breast and spreads to other tissues. A third type of breast cancer based 
on tissue type is also invasive and is a cancer that involves the ducts, lobules, and 
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lymphatics of the skin surrounding the breast. This form of breast cancer is called 
inflammatory breast cancer but is relatively rare.  
 
Although these differences in tissue type are important, the genetic and molecular 
profile-based classification scheme further defines breast cancer into groups based on 
differences in gene characteristics. There are four groups of breast cancer based on the 
molecular profiling: luminal, ERBB2, normal breast, and basal-like (4). High expression 
of many genes expressed by breast luminal cells is a feature of the luminal group. Of 
particular importance is the expression of the Estrogen Receptor (ER). ER positive 
breast cancers are sensitive to the hormone estrogen in that estrogen causes the cancer 
of this type to grow while ER negative breast cancers do not exhibit increased growth in 
the presence of estrogen. The second subgroup also expresses ER but at low levels. It 
is mainly characterized by overexpression of the oncogene ERBB2 or Her2/neu protein 
and bears that name.  
 
Similar to the second group, basal-like tumors do not express ER and the associated 
genes. These tumors are also referred to as the triple-negative breast tumors. The 
reason basal-like breast cancers are often referred to as triple-negative breast cancers is 
because they lack the expression of ER, the progesterone receptor (PgR), and ERBB2 
(Her2/neu protein). These triple-negative breast cancers are often associated with 
younger age onset, larger tumor sizes, and higher rate of lymph node involvement (4). 
No matter the type of breast cancer, improvements in early diagnosis as well as 
developing treatments with enhanced therapeutic efficacy are crucial to continuing the 
positive trends in death rates and improving not only overall survival but also quality of 
life for patients.  
 
 
Risk Factors and Diagnosis 
There are several risk factors associated with increased probability of developing breast 
cancer. Heredity is perhaps the most well defined risk factor studied to date. Inheritance 
of specific gene mutations in both oncogenes and tumor suppressor genes has been 
well characterized for many cancers including breast cancer. In fact, there are several 
inherited mutations associated with increased risk of breast cancer. For example, 
BRCA1 and BRCA2 are two well characterized breast cancer susceptibility genes (5).  
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BRCA1 is a tumor suppressor gene with a role in cell cycle surveillance and repair of 
DNA damage specifically through association with other factors resulting in activation of 
homologous recombination or non-homologous end-joining (NHEJ) (5, 6). BRCA2 has 
been found to bind BRCA1 and participate in the DNA damage response particularly in 
terms of activation of homologous recombination and double-strand break repair (5, 7). 
Mutations in these genes are variable in distribution but are consistent with a role in 
hereditary breast cancer. Mutations can cause a loss of function of these genes resulting 
in a decreased ability of the cell to repair damaged DNA (5, 6). Cells that cannot repair 
damaged DNA exhibit genomic instability that often involves loss of significant regions of 
DNA (8). Hereditary breast cancers do differ from sporadic breast cancer in 
characteristics so understanding the individual risks of inheriting certain genes is crucial. 
Not only are BRCA1 and BRCA2 markers of hereditary breast cancer risk but they are 
also important in defining treatment and prognosis. 
 
In addition to family history, age, a history of benign proliferative breast disorders, and 
endocrine factors are also major contributors to overall breast cancer risk. Recent 
studies have also linked an increased risk of breast cancer with obesity, diet, alcohol 
intake, and smoking (9-13). The importance of each of these factors in overall lifetime 
risk of developing breast cancer is still being evaluated. It is clear thus far that each 
factor alone is not sufficient to result in breast cancer but combined can lead to 
substantial risk for developing the disease. 
 
Establishing the family history and overall risk of an individual developing breast cancer 
is important to determining when to begin screening the individual for cancer. Early 
detection and diagnosis are crucial to generate improved prognosis and continue the 
steady decline in deaths. Breast cancer is diagnosed using a combination of tools 
including:  breast exam, mammography, ultrasound, breast magnetic resonance imaging 
(MRI), and biopsy of suspected lesions (1). In recent years genetic testing has also been 
a valuable tool especially for defining overall risk in hereditary cancers. Diagnosis via 
profiling protein markers is currently under investigation and could help in continuing 
early detection as well as providing a chance for better assessment of risk or even serve 
as markers for predicting cancer (14). These detection tools combined with a risk 
assessment are essential to defining the stage, prognosis, and treatment options for a 
particular patient. 
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Current Treatments and Therapies for Breast Cancer 
Treatment of breast cancer initially involves surgery. Surgical intervention can involve 
either partial or simple/total mastectomy to remove the affected tissue (1, 3). Based on 
the surgical options there are two general surgical approaches to treating breast cancer. 
The first, breast conservation therapy, requires a small enough ratio of tumor size to 
breast to ensure a successful removal of the entire tumor without significant damage to 
the appearance of the breast. This form of intervention attempts to eliminate the entire 
tumor while maintaining the overall appearance of the breast. Follow up to this form of 
surgery is whole breast irradiation.  
 
The second surgical approach is mastectomy. There are several forms of mastectomy 
based on patient desires for reconstruction of the breasts. Radical mastectomy involves 
complete removal of the breast without preservation of muscles. A modified radical 
mastectomy involves complete removal of the breast but the underlying musculature is 
not removed. In both cases lymph nodes are removed. An alternative to radical 
mastectomy, simple mastectomy, still involves removal of the breast; however, in simple 
mastectomy the lymph nodes are not removed. In addition to these types of mastectomy 
there are versions that attempt to spare the nipple and areola depending on the desires 
of the patient in terms of reconstruction. Although many of these specific surgical options 
are based solely on the desires of the patient in terms of aesthetics, it is important to 
note that the two general approaches to treating breast cancer do not differ in overall 
survival (3). 
 
Some breast cancers are advanced at the time of diagnosis and require additional 
intervention. It is therefore often important to provide adjuvant therapy to patients 
following surgery. Adjuvant and/or additional treatment options for breast cancer 
currently involve radiation therapy, hormone therapy and chemotherapy (1). Radiation 
therapy is widely used to supplement surgical intervention. Although there are multiple 
types of radiation therapies though external beam radiation, treatment involving a 
focused beam of radiation from an external source directed at the cancer cells, is the 
most common. Hormone therapy targets hormone responsive cancers and attempts to 
lower the hormone levels or block the effects of estrogen. Several drugs are available 
that target estrogen including aromatase inhibitors and tamoxifen (Nolvadex®) (1, 15). 
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These therapies act to stop the body from making estrogen or block its effects. 
Additional treatment for both localized and metastatic diseases involves chemotherapy. 
 
Chemotherapy utilizes medications to stop cell growth either through growth arrest or 
through direct cell killing. There are several chemotherapeutic drugs available with 
varying degrees of efficacy in breast cancer. These drugs are designed to target a wide 
range of cellular metabolic processes including but not limited to: microtubule formation, 
DNA repair, and telomerase activity (16, 17). Although there are significant positive 
outcomes associated with these therapies several limitations to these types of 
interventions exist. Chemotherapeutic strategies often have extensive side-effects and 
there are several instances of cancer developing resistance to the treatments (18, 19). 
 
It is important to note that due to recent advances in early detection, the majority of 
breast cancers can be cured by surgery; however, 10 to 40 percent of women whose 
axillary lymph nodes are clear of metastases at the time of surgery will develop distant 
recurrence (20). Even when surgery is followed by radiation treatment, 10 to 15 percent 
of women will develop recurrence within 10 years (3, 21). Given the risk of recurrence 
and issues of metastasis, continued research in treatments for advanced disease are 
essential. Studies have demonstrated that targeted therapies can be successful at 
increasing survival for patients. Therapies that target specific proteins such as the 
oncoprotein Her-2/neu or prevent blood vessel formation have promise as potential 
agents against metastatic disease (1). For example, Her-2/neu is found to be amplified 
in some cancers with an excess of this protein resulting in faster growth and spread of 
the cancer. A few agents have been developed to combat this increased growth. The 
monoclonal antibody, Trastuzumab (Herceptin), targets Her-2/neu by directly binding the 
protein and blocking its ability to trigger cancer cells to grow. Although these anti-Her-2 
therapies are effective in treating metastatic diseases for Her2/neu+ patients, each year, 
approximately 40,000 women in general still die from this disease making the 
development of new treatments critical.  
 
It is well known that the tumor and host immune system interact throughout tumor 
growth and cancer progression. Breast cancer in particular has been shown to be 
subject to immunosurveillance as evidenced by enhanced survival in patients exhibiting 
lymphocyte infiltration as well as the observed down-regulation of MHC molecules in up 
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to 50% of primary tumors and cell lines (22-26). These findings indicate that breast 
cancer could be treated using factors that promote anti-tumor immunity. 
 
 
Tumor Immunology 
Previous studies have demonstrated that tumor-associated antigens can be used to 
induce protective anti-tumor immunity capable of eliminating metastatic events, thus 
preventing or curing disease (27, 28). Additionally, cytokine therapy studies performed in 
animal tumor models have demonstrated potent therapeutic effects in eliminating tumors 
(29). However, translation of those studies to clinical practice requires more 
investigation. Current criticism of clinical immunotherapy includes the inability to 
effectively overcome self-tolerance as well as failure to adequately stimulate anti-tumor 
immunity. Nevertheless, β-interferon and interleukin-2 (IL-2) have been used in 
combination with tamoxifen (Nolvadex®) to treat hormone-dependent breast cancer 
patients with distant metastases and this regimen has demonstrated a survival benefit 
(30, 31). This observation indicates that anti-cancer immune responses can be induced 
by vaccination in situ to inhibit the growth of metastasis and protect patients from tumor 
recurrence. Other immune modulators have also been explored and may prove to illicit 
potent anti-cancer effects against metastatic disease; however, initiation of anti-tumor 
immunity alone may not suffice. The presence of immunosuppressive cells must also be 
considered. 
 
Tumor infiltration by immune suppressive cells coupled with T cell non-responsiveness is 
critical in tumor-associated immune evasion. The presence of cells capable of blocking 
immune activation both in the tumor and systemically limits the application of therapies 
meant to promote anti-tumor immunity. The overall immunosuppressive phenotype of 
the tumor microenvironment limits the efficacy of therapies that target immune activation 
(32). Understanding the role of suppressive cells in tumor progression and 
immunotherapy is essential to enhancing the effectiveness of therapies that target 
immune modulation. This is especially important in studies of cancer vaccination and 
attempts to promote a cell-type specific response (33). One population of immune 
modulators capable of suppressing T cell activation of particular interest in recent years 
is Myeloid-Derived Suppressor Cells (MDSC) (34-37).  
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Myeloid-Derived Suppressor Cells 
MDSC are a population of bone marrow-derived cells that express both the myeloid 
lineage differentiation antigen, Gr-1, and the αm integrin, CD11b, and exhibit the ability to 
suppress antigen-specific T cell activation. Gr-1/CD11b double positive cells represent 
approximately 20-30% of normal bone marrow cells, 2-4% of nucleated splenocytes, and 
are nearly absent in lymph nodes of healthy animals. These generic double positive cells 
differ from MDSC since they lack the ability to inhibit T cell activity (38-41). MDSC have 
been found to be expanded in a variety of carcinoma patients (42-45). Although some 
markers such as CD49d and interleukin-4 receptor α (IL-4Rα) have been implicated as 
markers of cells with suppressive function, these markers may not be limited to the 
suppressive Gr-1/CD11b double positive cells in all mouse models (44, 46).  
 
MDSC are a functionally suppressive, heterogeneous population of Gr-1/CD11b double 
positive cells composed of polymorphonuclear (PMN) cells and monocytes at early 
stages of myeloid differentiation. Several subpopulations have been identified; although 
the ratios of these distinct subpopulations of MDSC vary from strain to strain in the 
mouse models studied to date, there are unifying themes for MDSC (45, 47-51). All 
MDSC are of myeloid origin, are cells in an immature state, and exhibit a suppressive 
phenotype. It is clear from both the literature and the data contained within this 
dissertation that in order to be classified as an MDSC the cells must exhibit the ability to 
suppress T cell activation. The findings outlined in this dissertation also further 
demonstrate that this suppressive function is coupled with significant differences in 
overall phenotype. 
 
MDSC have been found to accumulate in the spleens, tumors, and lymph nodes of 
tumor-bearing animals and function to promote tumor progression as well as block 
immune responses through both antigen-specific and nonspecific mechanisms (52). 
Recently, MDSC have been isolated from the liver, with this site serving as a potential 
location for secondary expansion (53, 54). MDSC have a role in the regulation of 
autoimmune effector cells; however, in tumor progression, these cells act to suppress 
immune system activation and effectively block anti-tumor responses (55-57). MDSC 
have even been found to correlate with cancer stage and tumor burden (42, 58). 
Although MDSC are well characterized in terms of their immunosuppressive properties 
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and their role in cancer progression, angiogenesis, and metastasis, several other 
activities for these cells also exist (59).  
 
Recent studies have begun to define a role for MDSC in the following processes:  
regulation of immune responses during infection, acute and chronic inflammation, 
traumatic stress, surgical sepsis, chronic contact eczema, kidney allograft 
tolerance/transplantation, vessel formation post injury to muscle, inflammatory bowel 
disease, and demyelinating diseases (55, 56, 60-80). Now that both positive and 
negative roles for MDSC have been found, scientists have a better understanding of the 
importance of these cells in normal metabolic processes. The regulatory role these cells 
play in normal processes may be vital to controlling both innate and adaptive immune 
responses. Induction of these cells during tumor progression may be one of the more 
significant mechanisms through which tumors avoid challenge by the host immune 
system. 
 
 
MDSC Induction and Recruitment 
Profound alterations in myelopoiesis are associated with tumor growth. Induction and 
recruitment of MDSC through the promotion of myeloproliferation is a critical component 
to tumor progression (81). Factors produced by tumors are capable of triggering myeloid 
precursors to divide and sustain a level of immaturity associated with MDSC. MDSC 
accumulation in tumor-bearing animals occurs in response to a multitude of factors, 
especially those associated with chronic inflammation (56, 82, 83).  
 
Vascular endothelium growth factor (VEGF), granulocyte-macrophage colony stimulating 
factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin-6 (IL-6), and 
prostaglandin E2 (PGE2), in particular, have been shown to be inducers of MDSC 
accumulation with GM-CSF, G-CSF and IL-6 capable of acting on precursor cells in both 
humans and mice to generate MDSC (39, 71, 84-89). Interleukin-5 (IL-5) was recently 
discovered to be essential for MDSC recruitment to malignant pleural effusions, even 
though the actual production of IL-5 was found to be from the host cells rather than the 
cancer cells themselves (90). The tumor microenvironment promotes MDSC 
accumulation as evidenced by the production of cytokines and factors that cause their 
recruitment. Production of interleukin-1β (IL-1β) by tumors potently induces MDSC 
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accumulation as does tumor cell expression of c-kit ligand (86, 91-93). Interferon 
regulatory factor-8 has been shown to modulate the development of MDSC as well (94). 
Thus far, all studies indicate that these factors promote MDSC accumulation by 
promoting MDSC recruitment and proliferation from the bone marrow and myeloid 
precursors (95-97). It is important to note that stem-cell factor was shown to be vital for 
the accumulation of MDSC, though how it acts to induce suppressive cells remains to be 
determined (98).  
 
In addition to the other factors involved in inflammation, the proinflammatory S100 
proteins, S100A8 and S100A9, have been shown to have a role in MDSC accumulation 
(86, 99, 100). The role of these proinflammatory molecules in MDSC accumulation likely 
involves several mechanisms including direct cell signaling and chemoattraction. In fact, 
at least one chemoattracting pathway has been identified as having a role in MDSC 
recruitment: the CCL2/CCR2 pathway has been found to mediate the recruitment of 
MDSC though much about its involvement remains to be determined (101-103). The role 
of inflammation in tumor progression through the induction of MDSC is not only indicated 
by the effects of these proinflammatory cytokines, but also through studies that indicate 
a correlation between inflammation and the level of MDSC induction. Reductions in 
inflammation have been found to correlate with reduced MDSC accumulation (104). 
Though much has been determined in recent years regarding factors that induce MDSC 
recruitment, the mechanisms and pathways through which these factors promote MDSC 
proliferation and accumulation are still largely unknown. 
 
Many of the factors that induce MDSC proliferation also have a role in the activity of 
MDSC after their induction and recruitment to the tumor. For example, MDSC and M2 
macrophages (tumor-associated macrophages that exhibit a suppressive phenotype) 
recruited into the tumor microenvironment, up-regulate COX-2 expression and therefore 
exhibit enhanced PGE2 metabolism leading to enhanced production of immune 
modulators by the MDSC (105). This positive feedback mechanism may serve to not 
only promote the suppressive environment but may also be critical for tumor 
progression. The mechanisms through which MDSC influence the tumor 
microenvironment to evade anti-tumor immunity are of particular interest to defining how 
treatments might affect MDSC activity and immunosuppressive function. 
 
 10 
 
MDSC Activity and Tumor Progression 
MDSC have extensive roles in immune regulation and tumor progression. MDSC 
modulate immune surveillance of the tumor, inhibit the production of interferon-gamma 
(IFN-γ) by CD8+ T cells, induce apoptosis of CD4+ T cells, disrupt signaling through the 
T cell receptor (TCR), block T cell activation, subvert immunity toward a type 2 
suppressive response, regulate Th1 immunity, cause T-cell dysfunction, suppress T cell 
activation and expansion, and induce CD8+ T cell tolerance (72, 91, 106-117). These 
cells can also inhibit natural killer (NK) cell activity and NK cell utilization of IL-2 even in 
some cancer patients (118-121). There is evidence indicating that MDSC can suppress 
T cell activity in the tumor draining lymph node though additional experimentation is 
required to fully understand the roles of these cells in the lymph nodes (122). Although 
the focus thus far has been on the role these cells play directly on immune activators, 
there are several other activities exhibited by these cells that are important in cancer 
research. 
 
In addition to a role in immune regulation, MDSC are incorporated into the vascular 
endothelium and have been shown to promote tumor vascularization and progression 
(123-125). One mechanism through which they are known to induce angiogenesis is 
through the production of matrix metalloproteinase 9 (MMP-9) (126, 127). MDSC have 
also been shown to be important for tumor metastasis (128, 129). Although several 
activities have been identified much remains to be determined to further define the 
diverse roles of MDSC. 
 
There are several known mechanisms through which MDSC exert their suppressive 
activity including the production of reactive oxygen species, production of nitric oxide, 
triggering apoptosis of antigen-activated T cells, depletion of L-arginine via production of 
arginase, and sequestration of cysteine (82, 111, 130-140). An indirect mechanism 
through which MDSC suppress immune activation also exists. MDSC are capable of 
inducing T regulatory cell development though this mechanism may be specific to only a 
subset of animal models or tumor-types (110, 141-143). How these mechanisms are 
regulated and how that regulation might translate into use as a therapeutic target has 
been of particular interest in recent years. Treatment of MDSC with LPS and IFN-γ has 
been shown to activate the suppressive function of these cells implicating IFN-γ in the 
regulation of MDSC activity (144). Recent studies have also demonstrated that MDSC 
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suppressive activity is dependent on the C/EBPβ transcription factor, which indicates 
that certain transcription factors may be targets for altering MDSC suppressive function 
(71). Altering the suppressive activities of MDSC through depletion or differentiation of 
MDSC has been shown to result in restored T cell activation and stimulation of anti-
tumor immune responses making targeting these cells ideal for tumor immunologists 
(98, 145-150).  
 
Manipulation of MDSC activity stands as promising adjuvant to immunotherapeutic 
agents (36, 151, 152). The ability of a single-cytokine based therapy to work alone or in 
combination with an agent that alters MDSC accumulation or function has the potential 
to exhibit enhanced therapeutic efficacy through both the elimination of immune 
suppression and the activation of an anti-tumor immune response. Reductions in MDSC 
levels correlated with the induction of active macrophages but overall the alterations of 
MDSC had limited effects unless it was coupled with immune activation (40, 145, 147, 
153-158). This immune activation was typically via secondary means rather than a 
consequence of treatment with the primary agent. Studies have shown a reduction in 
metastasis coinciding with reductions in MDSC number or function, though, once again, 
these effects were associated with limited alterations in overall tumor growth unless 
immune activation was also induced (129, 145, 153, 154, 159). Treatment of tumor-
bearing animals as well as renal cell carcinoma patients with the tyrosine kinase 
inhibitor, sunitinib, was found to reverse MDSC accumulation and generate immune 
activation with significant therapeutic benefits (146, 160-162). Also, reductions in MDSC 
numbers in patients coupled with immune activation was also observed in a study 
involving GM-CSF therapy against melanoma (163). These studies imply that optimal 
therapeutic benefits can be obtained provided that the therapy target both reversing 
immune suppression and promoting immune activation simultaneously.  
 
Besides reductions in the number of MDSC, inhibition of function has shown promise as 
a therapeutic target. This was particularly true when peptide inhibitors were used to 
block transforming growth factor β (TGF-β) (164). Several factors are known to act 
directly on MDSC to alter their suppressive function; however, the overall therapeutic 
efficacy was limited (40, 98, 147, 148, 165). All Trans Retinoic Acid (ATRA), for 
example, was found to differentiate MDSC into mature myeloid cells by neutralizing their 
production of reactive oxygen species (ROS) (148, 166). However, in another study 
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involving ATRA, the  effects were limited even when administered as a combination 
therapy with a chemotherapeutic agent, cyclophosphamide (CTX), unless the therapy 
was administered during an optimal therapeutic timeframe (167). It is therefore of great 
importance to define the role that agents with proven therapeutic efficacy play in terms of 
MDSC in order to design improved therapies.  
  
Proinflammatory cytokines have potential as cancer immunotherapy agents, with 
interleukin-12 (IL-12), in particular, showing significant promise and effectiveness. The 
role of IL-12 in the tumor microenvironment is diverse and most likely involves the 
activation of multiple cell types including NK cells, T cells, and macrophages. Although 
IL-12 has been extensively studied on its own; however, the specific mechanism behind 
the ability of IL-12 to promote tumor regression, including why differences in treatment 
efficacy exist, remains to be fully understood. Defining the mechanisms of IL-12 activity 
and its ability to reverse immune suppression within the tumor microenvironment will 
continue to be of interest in future studies.  
 
 
Interleukin-12 
IL-12 is a disulfide-linked heterodimeric cytokine with potent anti-tumor activity. The 
biologically active 74 kDa protein is generated by the association of the p35 light chain 
and p40 heavy chain subunits. The p35 subunit is structurally similar to IL-6 and G-CSF 
while the p40 subunit is homologous to the exogenous region of the IL-6 receptor and is 
shared with interleukin-23 (IL-23) (168-172). The genes encoding mouse p35 and p40 
are located on chromosomes 6 and 11, respectively, while in humans, the p35 and p40 
genes are located on chromosomes 3 and 5, respectively (172). Given that the genes 
are located on separate chromosomes, their protein expression is regulated 
independently from one another with the p40 subunit capable of being produced as a 
free monomer or homodimer.  
 
 
IL-12 Production and the IL-12 Receptor 
IL-12 is produced by dendritic cells (DC), macrophages, monocytes, neutrophils, and to 
a lesser extent by B cells (173-176). The p40 subunit is expressed only in phagocytic 
cells that are also capable of producing the active heterodimer. The p35 subunit, 
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however, is constitutively and ubiquitously expressed at low levels. Production of the 
active IL-12 heterodimer occurs through both T cell-mediated and toll-like receptor 
mechanisms. The T cell-mediated mechanism involves engagement of receptor CD40L 
on T cells with CD40 on antigen presenting cells thus inducing IL-12 while the other 
means of production involves Toll-like receptor signaling induced by infection (172, 177-
180). Multiple pathogenic organisms and their products, including LPS, induce both the 
p40 subunit and the active heterodimer. 
  
IL-12 exerts its biological activity through the IL-12 receptor. The IL-12 receptor is 
composed of two subunits designated β1 and β2. The subunits are structurally related to 
the type I cytokine receptor superfamily and are homologous to glycoprotein 130 
(gp130), the IL-6 signal transducing chain (181-183). Although expression of one 
component of the receptor can be sufficient to trigger a response, expression of both 
subunits is essential for the generation of high affinity binding sites in humans (182). The 
IL-12Rβ1 subunit associates with the p40 subunit of IL-12 while IL-12Rβ2 associates 
with the p35 subunit and is the signal transducing chain.  
 
The IL-12R is expressed on activated T cells, NK cells, and DC (172, 184-187). It is 
important to note that resting T cells do not express the IL-12R; however, the receptor is 
induced upon T cell activation. This difference in IL-12R expression could explain why 
only activated T cells can proliferate in response to IL-12. The mechanism of this 
difference in IL-12 mediated stimulation of activated T cells may involve the T cell 
receptor (TCR). Signals through the TCR may play a role in instructing the up-regulation 
of the IL-12R (188). In addition to the differences between activated and resting T cells, 
Th1 cells express both IL-12Rβ1 and IL-12Rβ2 subunits while Th2 cells only express the 
IL-12Rβ1 subunit (189, 190). This implicates the β2 subunit as a potential determinant of 
Th phenotype differentiation. 
 
Although there are multiple factors that can induce IL-12 expression, there are also 
several cytokines that have inhibitory effects including:  interleukin-4 (IL-4), interleukin-
10 (IL-10), interleukin-11 (IL-11), interleukin-13 (IL-13), and transforming growth factor- β  
(TGF-β) (191-193). These cytokines not only inhibit protein secretion but also prevent 
the accumulation of p35 and p40 mRNA in stimulated antigen presenting cells. The role 
of IL-4 in blocking IL-12 production is somewhat controversial. Some studies have 
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demonstrated decreases in IL-12, while others indicated an increase in IL-12 (194-196). 
IL-4 has been demonstrated to block IL-12Rβ2 which could explain the reduction in IL-12 
activity as having been the result of IL-12R down-regulation (190, 197, 198). IL-10, on 
the other hand, is known to inhibit IFN-γ production from T cells and NK cells. The 
mechanism of this activity appears to be through the inhibition of IL-12 production by 
accessory cells (191).  
 
 
Biological Activity of IL-12 
IL-12 has several important biological functions. It plays a critical role in the interaction 
between innate and adaptive immunity. IL-12 has a role in innate immunity through its 
ability to promote IFN-γ production. IL-12 induces IFN-γ production predominantly in NK 
cells and both CD4+ T cells and CD8+ T cells (199). IFN-γ stimulates phagocytic cells 
promoting their bacteriocidal activity. IL-12 has a role in not only inducing IFN-γ 
production from cells but also in polarizing naive T cells into T helper cells (Th1). Th1 
cells are essential in the response against intracellular pathogens and through the 
production of IFN-γ and promotion of cell-mediated immunity. In addition to the 
production of IFN-γ, IL-12 stimulates T cell proliferation and enhances their cytolytic 
activity but only in activated T cells. This regulation of the adaptive immune response is 
a major function of IL-12. 
 
It is important to note that the induction of IFN-γ can result in a potent positive feedback 
loop whereby IL-12 induces IFN-γ that in turn induces macrophages to generate more 
IL-12 (200). These mechanisms to increase IL-12 production enable IL-12 to enhance 
the generation and activity of cytotoxic lymphocytes and promote cell-mediated immunity 
resulting in a potent inflammatory response. IL-12 is also capable of inducing further 
expression of the IL-12R. Binding of IL-12 to the receptor initiates JAK-STAT signaling 
(Janus Kinase-Signal Transducers and Activators of Transcription) through the tyrosine 
residues located on the β2 subunit (201-204). STAT1, STAT3, and STAT 4 have all 
been implicated in IL-12 signaling, though STAT4 appears to be the major factor in 
signal transduction (202-204). In addition to JAK-STAT signaling, IL-12 stimulation can 
also activate Lck (a Src family protein tyrosine kinase) and p38 (a mitogen-activated 
protein kinase/MAPK) (205-207).  
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Consequences of IL-12 Deficiency 
Mice deficient in either subunit of IL-12 or the IL-12R share similar phenotypes without 
obvious developmental abnormalities. Secretion of IFN-γ, NK cytolytic activity, and Th1 
differentiation are impaired in these animals, while Th2 development and IL-4 appear to 
be enhanced (208-210). Mice deficient in the p40 subunit of IL-12 are also deficient in IL-
23 and its associated functions, making these mice more immuno-compromised than 
p35-deficient mice (211). In addition to the loss of IL-12 activity, deficiencies in the IL-
12R exhibit a loss of STAT4 phosphorylation. The importance of STAT4 to IL-12 
signaling is supported by the analysis of STAT4 knockout animals. These mice exhibit 
defective IL-12 responses including IFN-γ production and Th1 differentiation (212). 
Deficiencies in STAT4 also result in impaired long-term CD8+ T cell responses (213). 
Treatment with exogenous IL-12 in some studies cannot reverse the loss of IFN-γ 
production, particularly in animals deficient in IL-12R. Deficiencies in IL-12 have also 
been shown to be important in cancer, as indicated by the correlation with greater risk to 
skin tumors as well as increased chance of malignant progression of the tumors (214, 
215).  
 
 
IL-12 and Cancer Immunotherapy 
IL-12 has been studied as a potential anticancer therapeutic agent in many different 
cancer types including: breast cancer, renal cancer, and prostate cancer (216, 217). The 
potential for IL-12 in cancer therapeutics is supported not only through past studies of 
efficacy but also in studies of the tumor microenvironment. Higher levels of intratumoral 
IL-12 expression in head and neck squamous cell cancers (HNSCC) and ovarian cancer 
was found to be associated with better survival (218-220). While increased expression is 
associated with better therapeutic outcomes, reductions in IL-12 expression in the tumor 
microenvironment have also been observed. MDSC, in particular, have been shown to 
suppress macrophage production of IL-12 within the tumor microenvironment through 
production of IL-10 (108). These findings indicate an important role for IL-12 as a 
potential anti-tumor agent with multiple activities. This importance of the expression of 
IL-12 in the tumor microenvironment is perhaps best illustrated by studies of the anti-
tumor activity of treatment with exogenous IL-12.  
 
 16 
 
Studies in IL-12 have indicated it has the potential to be the most effective single-
cytokine therapy capable of inducing solid tumor regression (221). IL-12 has also 
demonstrated the ability to inhibit the cell growth of leukemia (222, 223). The ability of IL-
12 to affect multiple tumor types makes it an ideal therapeutic agent for additional 
studies. In particular, IL-12 has significant promise as a treatment for breast cancer. 
Generating high localized levels of IL-12 has been shown to result in tumor regression in 
as many as 75% of treated murine breast tumors with 30% of animals exhibiting 
complete tumor regression (224). Complete tumor regression is also associated with 
immunity to subsequent challenge with fresh tumor cells. Several other studies utilizing 
gene therapy to induce tolerable levels of IL-12 have shown consistent reductions in 
tumor growth (216, 225-231).  
 
While therapies utilizing IL-12 alone have shown significant promise, IL-12 has also 
been studied in combination with chemotherapeutic agents as well as other 
proinflammatory cytokines. Studies of IL-12 in combination with Paclitaxel showed 
improved therapeutic efficacy including a reduction in metastasis without increased 
toxicity (232, 233). Combination of the chemokine fractalkine with IL-12 increased the 
activation of tumor infiltrating lymphocytes compared to fractalkine alone resulting in 
enhanced anti-tumor responses (234). IL-12 has also been tested with 
cyclophosphamide, IL-2, interleukin-15 (IL-15), interleukin-18 (IL-18), caspase 3, and 
IFN-γ inducible protein 10 (235-241). These studies indicated a variety of therapeutic 
results including enhanced IFN-γ expression and improved CD8+ T cell activation. 
 
While the specific mechanisms associated with positive clinical outcomes remain 
undefined, several studies have illuminated the role of IL-12 in both activating the 
immune system within the tumor microenvironment and fundamentally altering the tumor 
microenvironment itself. IL-12 is known to increase lymphocyte infiltration, inhibit tumor 
angiogenesis, and protect against metastasis (242-245). Rejection of metastatic disease 
has been associated with therapies that both promote immune responses and reverse 
immune suppression (246). IL-12 has proven to be one such factor. It is probable that 
the combination of IL-12 anti-tumor activity combined with the induction of active T cells 
results in the significant reductions in tumor growth and metastasis. 
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IL-12 not only increases lymphocyte infiltration it can also activate CD4+ Th1 cells, 
CD4+ Effector/Memory T cells, and CD8+ Cytotoxic T cells within the tumor 
microenvironment leading to potent antitumor effects (247-251). The effects of IL-12 on 
CD8+ T cells in particular are interesting in terms of cancer therapeutics. IL-12 has been 
shown to enhance CD8+ T cell cytotoxicity generating T cell-mediated antigen-specific 
antitumor activity (247, 252). CD8+ T cell based immunotherapies have even been 
applied in combination with IL-12 as a means to enhance the overall induction of 
endogenous anti-tumor responses (247, 253). IL-12 not only promotes immune 
activation but is also known to be capable of acting directly to reverse immune 
suppression. It accomplishes this through either the activation of T cells even in the 
presence of suppressive T regulatory cells or through inducing suppressor cell apoptosis 
(248, 254). In addition to these indirect mechanisms of antitumor activity, IL-12 is also 
capable of inducing direct tumor cell apoptosis through the induction of Fas and Fas 
Ligand (FasL) (255). Although IFN-γ is essential to promoting many of the activities of IL-
12, some of the antitumor effects of IL-12 are IFN-γ independent (235, 243). For 
example, IL-12 has a role in macrophage polarization and can alter the functional profile 
of both tumor-associated and tumor-infiltrating macrophages turning suppressive 
macrophages into inflammatory macrophages (256, 257). Overall, the ability of IL-12 to 
generate a transition in the tumor microenvironment from a suppressive environment to 
an activating one is essential to the overall effectiveness of IL-12-based therapies.  
 
Despite all of the benefits to IL-12 based therapies there are limitations. One limitation 
often associated with recombinant cytokines such as IL-12 is systemic toxicity. Systemic 
expression or delivery of IL-12 indicated a risk of toxicity to the liver and peripheral 
organs; however, Phase I and Phase II clinical trials have shown that the concentration 
of IL-12 used and  the treatment regimen may have been the critical factors in the 
observed toxicity (224, 258, 259). In addition to following careful regiments while giving 
the therapy, limiting the systemic expression of IL-12 to the tumor microenvironment 
could abrogate the potential toxic effects of the cytokine, though if levels remain below 
tolerable doses, this is an unnecessary precaution. Several studies of IL-12 in murine 
models have demonstrated limited toxicity at levels of IL-12 capable of inducing 
significant therapeutic effects particularly when IL-12 is administered via recombinant 
adenovirus (224, 225, 258, 260).  
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Adenovirus and Its Therapeutic Applications with IL-12 
Direct delivery of a gene expression cassette into a target cell by a viral vector is the 
ideal means through which expression of the gene can target a specific cell and achieve 
enhanced therapeutic efficacy with limited toxicity. To date, the most commonly used 
virus for human gene therapy clinical trials is adenovirus. Adenovirus is a double-
stranded DNA, non-enveloped, icosahedral virus. It stands as a potential gene therapy 
agent due to its safety, gene capacity, ability to infect multiple human cell types, and 
ability to infect cells regardless of cell cycle status. In terms of generating therapeutic 
vectors, adenovirus is also an attractive virus in that it is easily manipulated, can 
generate high titers, and is relatively inexpensive to generate.  
 
Adenovirus has been used as a vector to express many different cytokines to be utilized 
as cancer therapies. Of interest in these studies is the used of adenovirus to express IL-
12. In situ expression of IL-12 via adenoviral vectors has the potential to induce a potent 
anti-tumor immune response. Several studies indicated that adenovirus containing IL-12 
alone could eliminate an established tumor via intra-tumor injection of the virus. 
Bramson et al. treated 36 tumors with one single intra-tumor injection of adenovirus 
containing IL-12 and observed that 11 completely regressed (31%) and 17 partially 
regressed (224). Animals with complete tumor regression had protective immunity 
against re-challenging with fresh tumor cells. High levels of IL-12 expression were 
observed both in tumors (600-800 ng per tumor) and serum (40 to 60 ng/ml) 24 hours 
after virus injection without apparent systemic toxicity (224). However, this study only 
analyzed IL-12 expression in 2 animals from each treatment group, and did not attempt 
to correlate IL-12 expression with the therapeutic effect nor explain why some animals 
exhibited a complete response and others only partially responded or failed to respond. 
Another study performed by Gambotto et al. demonstrated moderate levels of serum IL-
12 expression (8 ng/ml) via intra-tumor injection of adenovirus containing IL-12, resulting 
in eliminating 80% of treated tumors (261). Chen et al. was able to eliminate all but one 
tumor with intra-tumor injection of adenovirus containing IL-12; however, they did not 
report the concentration of IL-12 in the serum (262). In contrast, the majority of studies 
indicated that adenovirus-mediated IL-12 was not very effective in eradicating a tumor 
burden by itself, and required cooperation with another immune modulator, such as 
CD137 (4-1BB) (263), CD80 (B7.1) (264), or GM-CSF (265). Most of those studies either 
did not investigate serum levels of IL-12 expressed by the treatment or observed low 
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serum levels (0.6 to 2.5 ng/ml) and did not correlate those serum levels with the 
therapeutic effect (260, 266).  
 
   
Dissertation Overview 
The role of tumor associated immune regulation through the presence of 
immunosuppressive cells is relatively well established. However, the effects of IL-12 on 
immunosuppressive cells such as MDSC remain to be fully understood. I hypothesized 
that IL-12 is capable of reversing the suppressive effects of MDSC while simultaneously 
promoting immune activation. The first aim of this dissertation was to identify whether IL-
12 acts directly on MDSC to alter their suppressive function. The second aim of this 
dissertation was to characterize the effect of IL-12 on MDSC and the mechanism of IL-
12 activity. The third aim of this dissertation was to determine the therapeutic efficacy of 
treatment with AdIL-12 and determine a potential role for the IL-12 effect on MDSC as a 
contributing factor to the therapeutic efficacy of the treatment. The findings are 
summarized in figure 1. 
 
 
Figure 1. Effects of IL-12 on 
MDSC. MDSC are known to alter 
T cell activity through induction of 
apoptosis or T cell anergy. MDSC 
exert this activity through the 
production of reactive nitrogen 
species and arginase. I 
hypothesized that IL-12 can act to 
alter the production of IFN-γ, 
Nos2, and ArgI thus altering the 
activity of the MDSC. In addition, I 
hypothesized that IL-12 promotes 
MDSC maturation. 
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Materials and Methods 
 
Mice and Cell Culture 
C3H/HeJ and Balb/c mice were obtained from the Jackson Laboratory (Bar Harbor, ME). 
Murine breast cancer cell lines C3L5 (Dr. P. K. Lala, The University of Western Ontario, 
Canada) and 4T1 (ATCC, Manassas, VA) were maintained in RPMI 1640 and DMEM, 
respectively. All media was supplemented with 10% fetal bovine serum (FBS) and 1% 
Penicillin/Streptomycin. Cells were fed fresh growth media three times per week and 
maintained at 37°C in a 5% CO2 incubator.  
 
 
Generation of Gr-1/CD11b Double Positive Cells for Analysis 
2.5 x 105 C3L5 cells and 1 x 105 4T1 cells were injected into the mammary fat pads of 
C3H/HeJ and Balb/c mice, respectively, to induce mammary tumors. Gr-1/CD11b double 
positive cells were found to expand in the tumors and spleens. Animals were sacrificed 
once tumors reached a size of 500 mm3. Tumor specimens were surgically removed and 
processed by cutting into small pieces and digested with 5 U/ml collagenase (Roche, 
Germany) and 5 μg/ml DNase I in RPMI 1640 (10% FBS, 1% Penicillin/Streptomycin) at 
37°C for 1.5 hours. The resulting mixture was filtered through 40 μm nylon mesh. The 
cells were washed with fresh RPMI and red blood cells (RBC) were lysed via culture in 
1X ACK/RBC lysis buffer at room temperature for 3 minutes. Cells were washed and 
maintained in RPMI 1640 (10% FBS, 1% Penicillin/Streptomycin). Spleens were also 
surgically removed, mashed, and RBC were lysed using the same process as with the 
digested tumor.  
 
 
Isolation of Gr-1/CD11b Double Positive Cells 
Whole splenocytes and cells from the digested tumors were stained using standard 
protocols with fluorochrome-conjugated antibodies, anti-Gr-1 (BD Bioscience, San 
Diego, CA) and anti-CD11b (BD Bioscience). Briefly, cells were washed with 1X PBS. 
Antibody was added at a concentration of 2 μg/ml of fluorochrome-conjugated antibody 
in 1X PBS with 1% bovine serum albumin (BSA) or 2 μg/ml mouse IgG (blocking agents; 
BD Bioscience) for 20 minutes at 4°C (BD Bioscience). Cells were washed with 1X PBS, 
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resuspended in RPMI supplemented with 1% FBS and 1% Penicillin/streptomycin, and 
sorted via flow cytometry at the Flow Cytometry Core Facility (IUPUI, Indianapolis, IN). 
 
 
Analysis of the expression of both subunits of the IL-12R 
Sorted GR-1/CD11b double positive cells along with whole splenocytes and digested 
tumor cells were stained with fluorochrome-conjugated anti-IL-12Rβ1 antibody and a 
combination of anti-IL-12Rβ2 primary antibody with fluorochrome-conjugated secondary 
antibody (BD Bioscience) in combination with fluorochrome-conjugated anti-Gr-1 and 
anti-CD11b antibodies. Each antibody was used at a concentration of 2 μg/ml. Cells 
were blocked with 1% BSA or 2 μg/ml mouse IgG (BD Bioscience). NK cells were 
stained with 2 μg/ml fluorochrome-conjugated pan NK cell marker clone DX5 antibody 
(eBioscience, San Diego, CA), fluorochrome-conjugated anti-IL-12Rβ1 antibody, and the 
combination of 2 μg/ml anti-IL-12Rβ2 primary antibody and 2 μg/ml fluorochrome-
conjugated secondary antibody as a positive control. Naïve CD4+ T cells were stained 
with 2 μg/ml fluorochrome-conjugated anti-CD4 antibody (eBioscience), 2 μg/ml 
fluorochrome-conjugated anti-IL-12Rβ1 antibody, and the combination of 2 μg/ml anti-IL-
12Rβ2 primary antibody and 2 μg/ml fluorochrome-conjugated secondary antibody as a 
negative control. Analysis of the expression of the IL-12R was performed via flow 
cytometric analysis using a FACScalibur (Becton Dickinson, Mountain View, CA).  
 
 
5-(and 6-)Carboxyfluorexcein diacetate succinimidyl ester(CFSE) labeling of cells 
Cells were labeled with CFSE according to manufacturer’s protocols (Cell Trace CFSE 
Cell Proliferation Kit, Invitrogen, Eugene, OR). Briefly, CFSE is diluted in DMSO at a 
stock concentration of 5 mM which is freshly diluted to a working concentration of 10 μM. 
Whole splenocytes were suspended at a concentration of 1 x 107 cells/ml in PBS 
containing 0.1% BSA and combined with the 10 μM working concentration of CFSE. 
Following a 10 minute incubation period at 37°C, the CFSE labeling was stopped by 
adding 5 times volume of ice cold RPMI (10% FBS, 1% penicillin/streptomycin) and 
incubating on ice for 5 minutes. The CFSE labeled cells were washed 3 times with ice 
cold fresh RPMI (10% FBS, 1% penicillin/streptomycin) and resuspended to the desired 
concentration. 
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In vitro stimulation of T cells 
CFSE labeled cells were plated in 96-well plates at a density of 1 x 106 cells/ml in RPMI 
(10%FBS, 1% penicillin/streptomycin) and incubated with or without 5 μg/ml soluble anti-
CD3 (eBioscience) and anti-CD28 (BD Bioscience) antibodies alone or in combination 
with sorted Gr-1/CD11b double positive cells in a 1:1 ratio for a total cell density per well 
of 2 x 105 cells. For analysis of the effect of IL-12, labeled cells and sorted Gr-1/CD11b 
double positive cells were incubated with 10 ng/ml recombinant IL-12 separately for 24 
hours at 37°C, washed, and then co-cultured. Cells were incubated for 4 days at 37°C. 
After this incubation period, cells were harvested and labeled with fluorochrome-
conjugated anti-Gr-1 antibody for identification and elimination of the Gr-1+/CD11b+ 
subset using a FACScalibur (Becton Dickinson). A small sample of cells was also 
labeled with fluorochrome-conjugated anti-CD4 and anti-CD8 antibodies (eBioscience) 
to identify the profile of lymphocytes for gating and analysis of lymphocyte activation 
using a FACScaibur (Becton Dickinson). One hundred thousand total events from 
triplicate wells were collected and analyzed for lymphocyte activation based on loss of 
CFSE intensity.  
 
 
Analysis of changes in surface markers 
Sorted Gr-1/CD11b double positive cells from C3H/HeJ and Balb/c naïve spleens, 
tumor-bearing spleens (C3L5 and 4T1 respectively), and digested tumor were incubated 
with or without 10 ng/ml recombinant IL-12 for 24 hours. Cells were stained with 
antibodies at a concentration of 2 μg/ml in 1X PBS containing 1% BSA or 2 μg/ml mouse 
IgG for 20 minutes at 4°C. Cells were washed with 1X PBS and fixed in 1% 
paraformaldehyde. Antibodies were all fluorochrome-conjugated and included anti-
CD86, anti-CD80, anti-F4/80, and anti-MHCII antibodies (eBioscience). Analysis for 
expression of these markers compared to whole splenocytes positive controls and CD4+ 
T lymphocytes negative controls was performed via flow cytometry using the 
FACScalibur (Becton Dickinson).  
 
 
Real Time Polymerase Chain Reaction (PCR) 
Sorted Gr-1/CD11b double positive cells from naïve and tumor-bearing animals were 
treated for 24 hours with 10 ng/ml IL-12. Cells were lysed and RNA was extracted using 
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the RNAeasy kit (E.Z.N.A. homogenizing columns and E.Z.N.A. RNA Extraction Kit, 
Quanta Biosciences Inc., Gaithersburg, MD). RNA was converted to cDNA via PCR 
reaction with the qScript cDNA Supermix (Quanta Biosciences Inc., Gaithersburg, MD). 
The RT step protocol was performed on the PTC-100 (MJ Research Inc., Gaithersburg, 
MD) thermocycler and involved the following 3 steps: 5 min at 25°C, 30 min at 42°C, and 
5 minutes at 85°C. Taqman primer probes against Nos2, IFN-γ, ArgI, IL-10, and tumor 
necrosis factor (TNF) were purchased from Applied Biosystems (ABI, Carlsbad, CA). 
The concentration of RNA was obtained via analysis of OD260 verses OD280 readings 
and cDNA was diluted in EB buffer so that total concentrations were equal for all 
samples. Using the PCR master mix also obtained from ABI, semi-qualitative real time 
PCR was performed (ABI). The real time PCR was performed on the ABI 7500 Real 
Time PCR Machine using the following protocol:  10 minutes at 95°C and 40 cycles of 15 
seconds at 95°C followed by 1 minute at 65°C (data recorded during this 65°C stage). 
 
 
Generation of Recombinant Adenovirus 
Adenovirus vectors were generated using methodology previously described though 
modified to contain the desired genes and without prostate specificity (267). Adenovirus 
containing a luciferase expression cassette (AdLuc) or a recombinant IL-12 expression 
cassette (AdIL-12) was used as a control for virus effect and to generate IL-12, 
respectively. Briefly, plasmids containing IL-12 or luciferase under control of CMV 
promoters are packaged into virus using packaging cells.  Virus is then amplified and 
purified prior to use. 
 
 
Enzyme-linked immunosorbent assay (ELISA) 
Serum from AdLuc or AdIL-12 treated animals was harvested for analysis of IL-12 and 
IFN-γ. Sorted Gr-1/CD11b double positive cells were treated with 10ng/ml IL-12 for 24 
hours. Media was harvested for the analysis of protein concentration with and without IL-
12 treatment. Concentrations of proteins were determined via ELISA kits for IL-12, IFN-
γ, IL-10 and TNF-α (BD Bioscience). Briefly, ELISA plates are coated with a capture 
antibody overnight. The capture antibody is blocked for 1 hour with assay diluent (1X 
PBS with 10% FBS), washed with wash buffer (1X PBS with 0.05% Tween-20), and then 
incubated with samples and standards for 2 hours. Wells are washed and treated with 
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detection antibody combined with streptavidin-horseradish peroxidase for 1 hour. Cells 
are washed again and treated with substrate solution (BD Bioscience). The reaction is 
stopped with 2N H2SO4 and read using the plate reader at 450nm. 
 
 
In vivo Analysis of IL-12 Effect on MDSC 
Tumors were generated as described previously and allowed to grow to roughly 300 
mm3 in volume. Prior to treatment, serum was harvested to establish baseline levels of 
IL-12 in the tumor-bearing animals. 1 x 109 adenovirus particles suspended in 40 μl of 
1X PBS were injected intramuscularly into the animals. Twenty-four hours after 
treatment, serum, tumors, and spleens were harvested for further analysis. Serum was 
used to demonstrate IL-12 production while digested tumors and spleens were analyzed 
for changes in the Gr-1/CD11b double positive cells as described for the in vitro 
experiments. 
 
 
In Vivo Treatment of Established Tumors 
Tumors were also allowed to grow to approximately 65 mm3 as described previously and 
treated with intramuscular injections of 1 x 109 adenovirus particles suspended in 40 ul 1 
x PBS of either AdIL-12 or AdLuc (268, 269). Tumors were measured twice weekly using 
calipers until tumors grew to approximately 500 mm3. Animals were humanely sacrificed 
and tissues were harvested for further analysis as described previously. Frozen sections 
of tumor were prepared. Tumors were analyzed for histology via hematoxylin and eosin 
(H&E) staining as well as for changes in the Gr-1/CD11b double positive cell populations 
via flow cytometry. Single cell suspensions of tumors were stained with anti-Gr-1, anti-
CD11b, anti-CD8, anti-IFN-γ, and anti-CD45 (BD Biosciences) antibodies and analyzed 
via flow cytometry. Lungs were stained in Bouin’s Fixative (LabChem Inc., Pittsburg, PA) 
and metastases counted. 
 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 5.01 for Windows (GraphPad 
Software, San Diego, CA). Statistical significance was defined as a p value < 0.05 with 
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the actual p values indicated where appropriate. Analysis was performed on at least 3 
individual experiments as indicated. 
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Results 
 
Gr-1/CD11b double positive cells are expanded in the tumors and spleens of 
tumor-bearing animals and vary in morphology 
Tumor progression promotes an increase in Gr-1/CD11b double positive cells in all 
murine breast cancer models studied to date; however, the type of cells induced during 
tumor progression has been found to vary based on animal strain and tumor type (45-
52). Differences in the composition of the cells can factor into the overall activity and 
response to treatment. Gr-1/CD11b double positive cells can be either monocytic or 
PMN in nature though in both instances functionally suppressive Gr-1/CD11b double 
positive cells (MDSC) are immature versions of these cell types. Analysis of the Gr-
1/CD11b double positive cells in the animal models of interest is essential to generating 
a complete understanding of differences in response to treatment that may occur. 
 
Although it has been determined that Gr-1/CD11b double positive cells are expanded in 
the tumors and spleens following tumor progression for the murine models studied thus 
far, it was necessary to confirm this in the murine models of interest for these studies as 
well as for our experimental conditions. C3H/HeJ and Balb/c mice were selected as 
models for this study due to their potential for differences in the composition of Gr-
1/CD11b double positive populations. C3L5 and 4T1 murine cell lines were injected into 
the mammary fat pads of C3H/HeJ and Balb/c animals, respectively. Figure 2 
demonstrates that these Gr-1/CD11b double positive cells are expanded in the spleens 
and can be found in the tumors of both models following tumor development. The 
expression of Gr-1/CD11b double positive cells in the spleens of animals bearing tumors 
averaging approximately 500 mm3 in volume significantly increases to an average of 
20% of all splenocytes in C3H/HeJ animals bearing C3L5 tumors and 25% in Balb/c 
animals bearing 4T1 tumors compared to less than 5% in naïve animals of both strains. 
In terms of the concentration of Gr-1/CD11b double positive cells in the tumor, an 
average of approximately 12% of the entire tumor was observed to be Gr-1/CD11b 
double positive cells. In addition to the slight differences in levels of induction, the 
composition of the Gr-1/CD11b double positive cells in C3H/HeJ animals was found to 
differ in percentages of cell type compared to from those isolated from Balb/c animals 
(Figure 3).  
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Figure 3 represents the findings regarding the morphology of Gr-1/CD11b double 
positive cells. C3H/HeJ-derived Gr-1/CD11b double positive cells were found to be 
predominantly monocytes while Gr-1/CD11b double positive cells from Balb/c animals 
were found to be composed of a ratio of approximately 2:3 PMN to monocytes. By 
selecting two models that differ in MDSC composition, comparisons in responsiveness to 
the same treatment can be performed, enabling a better overall understanding of the 
nature of functionally suppressive Gr-1/CD11b double positive cells. 
 
 
 
Figure 2. Gr-1/CD11b double positive cells are expanded in the spleens of tumor-
bearing animals and are present in tumors. C3H/HeJ (A) and Balb/c (B) animals were 
injected with 2.5 x 105 C3L5 and 1 x 105 4T1 cells, respectively. Tumors were allowed to 
grow to 500 mm3 in volume and tissues were harvested and single-cell suspensions 
obtained. Cells were stained with fluorochrome-conjugated anti-Gr-1 and anti-CD11b 
antibodies at a concentration of 2 μg/ml. Cells were then analyzed for Gr-1/CD11b 
double positive cell populations in tumors and spleens as compared to spleens of naïve 
animals from both strains via flow cytometry. The concentration of Gr-1/CD11b double 
positive cells was determined as a percentage of the whole tissue analyzed. Graphs 
represent percentages of cells obtained from 10 animals per group (n = 10; **p < 0.01). 
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Figure 3. The population of 
tumor-induced Gr-1/CD11b 
double positive cells includes 
both monocytes and PMNs. 
Morphological analysis of Gr-
1/CD11b double positive cells 
from tumor bearing animals 
was performed. Single cell 
suspensions from the spleens 
of tumor-bearing animals 
were stained with 
fluorochrome-conjugated anti-
Gr-1 and anti-CD11b 
antibodies and sorted for 
double positive cells via flow cytometry. Cells were placed onto slides via the cytospin 
procedure and stained using the Diff Quick staining protocol. Analysis was performed via 
microscope analysis of cell morphology on triplicate slides (n = 3). The graph represents 
the percent of PMN cells.  
 
 
Gr-1/CD11b double positive cells from tumor bearing animals are functionally 
suppressive MDSC 
In order to assess the nature of Gr-1/CD11b double positive cells in terms of their 
suppressive activity, the ability of these cells to suppress CD3-mediated T cell activation 
was defined. CD3 is a component of the TCR and suppression of this type of signaling 
can be used to demonstrate an ability to suppress T cell responses. Anti-CD3 antibody 
can bind to the TCR/CD3 complex and induce cell signaling resulting in T cell activation 
in the same manner as antigen presentation from antigen-presenting cells (APC). When 
stimulation through the TCR is combined with stimulation through the co-receptor 
optimal activation can be observed. Using this principle, cells were treated with a 
combination of anti-CD3 and anti-CD28 antibodies and analyzed via T cell activation 
assays.  
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T cell activation assays measure the amount of activation by demonstrating a change in 
CFSE concentration as cellular division occurs. CFSE is a cytoplasmic dye that is 
equally divided along with the cytoplasm during cell division. As a T cell is stimulated, it 
is signaled to proliferate and this proliferation can be measured by a dilution of the CFSE 
cytoplasmic stain with each division. Suppression of T cell activation was determined via 
flow cytometric analysis of CFSE dilution following treatment of cells with anti-CD3 and 
anti-CD28 antibodies for 4 days.  
 
Gr-1/CD11b double positive cells were stained with fluorochrome-conjugated antibodies 
and isolated from the spleens of naïve animals as well as the tumors and spleens of 
tumor-bearing animals. These cells were then cultured with CFSE-stained whole 
splenocytes at a 1:1 ratio. Results for C3H/HeJ spleen- and tumor-derived Gr-1/Cd11b 
double positive cells are shown in figure 4 while Balb/c spleen- and tumor-derived cells 
are shown in figure 5. 
 
As figures 4 and 5 demonstrate, co-culture of T cells with Gr-1/CD11b double positive 
cells at a 1:1 ratio resulted in suppression of T cell activation but this was dependent on 
the origin of the Gr-1/CD11b cells. The figures are representative of 3 individual 
experiments of cells assayed in triplicate. Gr-1/CD11b double positive cells from tumor-
bearing animals significantly suppressed T cell activation regardless of whether they 
were harvested from the spleen or tumor (p < 0.01). Percent activation from the positive 
controls was found to involve up to 60 percent of the total CD4+ T cell population. Co-
culture with MDSC was found to suppress this activation to as little as 7 percent of the 
CD4+ T cell population. It is essential to note that Gr-1/CD11b double positive cells from 
naïve animals were not capable of significantly suppressing T cell activation (p > 0.05). 
Although there does appear to be low levels of suppression, the levels of activation for 
the CD4+ T cells remain within the range of activation levels observed in the positive 
control treatment group. This difference in ability to suppress T cell activity supports the 
concept that critical differences exist between functional MDSC and cells that are merely 
Gr-1/CD11b double positive cells. It also demonstrates that the method of study and 
analysis outlined in this dissertation does not cause the Gr-1/CD11b double positive 
cells to become suppressive. Gr-1/CD11b double positive cells derived from naïve 
animals are not suppressive; therefore, suppressive activity is a factor of a specific 
subtype of Gr-1/CD11b double positive cells, not a factor of the experimental conditions. 
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Functionally suppressive Gr-1/CD11b double positive cells will be described as MDSC 
for the remainder of the dissertation. 
 
 
Figure 4. Gr-
1/CD11b double 
positive cells 
derived from 
C3L5 tumor-
bearing C3H/HeJ 
animals are 
suppressive 
MDSC. Whole 
splenocytes from 
C3H/HeJ animals 
were stained with 
10 μM CFSE and 
co-cultured with 
sorted Gr-
1/CD11b double 
positive cells at a 
1:1 ratio for a 
total of 2 x 105 
cells per well. 
Cells were 
treated with 5 
μg/ml anti-CD3 
and anti-CD28 antibodies in 96 well plates for 4 days. The cells were harvested and 
stained with anti-Gr-1 and anti-CD4 antibodies to isolate only CD4+ T cells for analysis. 
Cells were gated for CD4+ T cells only and analyzed for dilution of CFSE via flow 
cytometry. A negative control of unstimulated splenocytes (A) and a positive control of 
stimulated splenocytes only (B) were compared to splenocytes activated in the presence 
of Gr-1/CD11b double positive cells from the spleen of naïve animals (C) and Gr-
1/CD11b double positive cells from the spleen (D) and tumor (E) of tumor-bearing 
 31 
 
animals. Graphs are representative of three independent experiments. Percentages 
indicate percent activation. 
 
 
Figure 5. Gr-
1/CD11b double 
positive cells 
derived from 
4T1 tumor-
bearing Balb/c 
animals are 
suppressive 
MDSC. Whole 
splenocytes 
from Balb/c 
animals were 
stained and 
cultured as 
described 
previously 
(Figure 4). A 
negative control 
of unstimulated 
splenocytes (A) 
and a positive 
control of 
stimulated 
splenocytes only (B) were compared to splenocytes activated in the presence of Gr-
1/CD11b double positive cells from the spleen of naïve animals (C) and Gr-1/CD11b 
double positive cells from the spleen (D) and tumor (E) of tumor-bearing animals. 
Graphs are representative of three independent experiments. Percentages indicate 
percent activation. 
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MDSC express IL-12Rβ1 and IL-12Rβ2 
Treatment of MDSC with factors known to alter their suppressive activity has shown 
some promise in terms of therapeutic efficacy (40, 145, 147, 153-158). As discussed 
previously, several cytokines have been shown to alter MDSC activity but with limited 
therapeutic effect (154-157). The effects of IL-12 on MDSC activity remains to be 
defined. IL-12 is of particular interest in tumor studies due to its demonstrated efficacy 
and potential to activate anti-tumor immune responses. In order to determine whether IL-
12 could impact MDSC directly rather than through the activation of secondary cells, I 
first determined whether these cells exhibit the necessary receptor for IL-12-mediated 
activity.  
 
Using fluorochrome-conjugated antibodies, I tested whether Gr-1/CD11b double positive 
cells express the IL-12 receptor. NK cells stained with NK marker antibodies, NK1.1 or 
NK clone DX5, served as a positive control for IL-12R expression while naïve, 
unstimulated CD4+ T cells served as a negative control. I determined whether Gr-
1/CD11b double positive cells from naïve animals as well as MDSC express either or 
both of the IL-12Rβ1 and IL-12Rβ2 subunits (Figures 6 and 7; Table 1). Figure 6 
represents the histogram analysis of IL-12Rβ1 expression for Gr-1/CD11b double 
positive cells and figure 7 represents the histogram analysis of IL-12Rβ2 expression for 
Gr-1/CD11b double positive cells. Naïve C3H/HeJ spleen-derived Gr-1/CD11b double 
positive cells do not express the IL-12Rβ1 subunit but they do express the IL-12Rβ2 
subunit (Figure 6 A and Figure 7 A). Naïve Balb/c spleen-derived Gr-1/CD11b double 
positive cells express both of the receptor subunits (Figure 6 D and Figure 7 D). MDSC 
derived from tumor bearing animals of both strains were also studied. Figure 6 B and C 
represents IL-12Rβ1 expression of C3H/HeJ C3L5 tumor-bearing animals’ spleen-
derived and tumor-derived cells, respectively. Figure 6 D and E represents IL-12Rβ1 
expression of Balb/c 4T1 tumor-bearing animals’ spleen-derived and tumor-derived cells, 
respectively. Figure 7 B and C represents IL-12Rβ2 expression forC3H/HeJ C3L5 tumor-
bearing animals’ while D and E represents the expression of IL-12Rβ2 for Balb/c 4T1 
tumor-bearing animals’ spleen-derived and tumor-derived MDSC respectively. MDSC 
were found to express both subunits (Figure 6 B, C, E, and F and Figure 7 B, C, E, and 
F). Changes were regardless of whether the MDSC are derived from tumors (Figures 6 
and 7 E and F) or spleens (Figures 6 and 7 C and D) of the tumor bearing animals. The 
results are summarized for whether the marker is expressed (+) or not (-) in table 1. 
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Figure 6. 
Expression of 
IL-12Rβ1 on the 
surface of Gr-
1/CD11b double 
positive cells. 
Single cell 
suspensions of 
tissues from 
tumor-bearing 
and naïve 
animals were 
obtained and 
stained with 
fluorochrome-
conjugated anti-
IgG, anti-Gr-1, 
anti-CD11b, 
anti-NK1.1 
(Balb/c), anti-NK 
clone DX5 
(C3H/HeJ), and 
anti-IL-12Rβ1 
antibodies at a 
concentration of 
2 μg/ml. Cells 
were analyzed for expression of the receptor above anti-IgG control antibody expression 
(black line) via flow cytometry. The red line represents the positive control NK cells while 
the blue line represents the Gr-1/CD11b double positive cells. C3H/HeJ-derived cells 
from the spleens of naïve animals (A) spleens of tumor-bearing animals (B) and tumors 
(C) are represented. Also represented are cells derived from the spleens of naïve Balb/c 
animals (D), spleens from tumor-bearing animals (E), and tumors (F).  
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Figure 7. 
Expression of IL-
12Rβ2 on the 
surface of Gr-
1/CD11b double 
positive cells. 
Single cell 


tumor-bearing 
and naïve 
animals were 
obtained and 
stained with 
fluorochrome-
conjugated anti-
IgG, anti-Gr-1, 
anti-CD11b, anti-
NK1.1 (Balb/c), 
and anti-NK clone 
DX5 (C3H/HeJ), 
antibodies at a 
concentration of 2 
μg/ml. IL-12Rβ2 
was also stained 
via anti-IL-12Rβ2 
primary antibody followed by fluorochrome-conjugated anti-IgG secondary antibody both 
at a concentration of 2 μg/ml. Cells were analyzed for expression of the receptor above 
anti-IgG control antibody expression (black line) via flow cytometry. The red line 
represents the positive control NK cells while the blue line represents the Gr-1/CD11b 
double positive cells. C3H/HeJ-derived cells from the spleens of naïve animals (A) 
spleens of tumor-bearing animals (B) and tumors (C) are represented. Also represented 
are cells derived from the spleens of naïve Balb/c animals (D), spleens from tumor-
bearing animals (E), and tumors (F). 
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Table 1. Summary of IL-12Rβ1 and IL-12Rβ2 Expression on the Surface of Gr-1/CD11b 
Double Positive Cells. In the table, (+) designates expression of the receptor; (-) 
designates that the receptor is not expressed.  
 
 
IL-12 alters the suppressive function of MDSC 
After determining that MDSC from tumor-bearing animals are functionally suppressive 
and express the IL-12R on their plasma membranes, we sought to define the role that 
IL-12 could have on these cells. We sought first to determine whether IL-12 had any 
effects on the cells in terms of altering MDSC suppressive function. If IL-12 could reduce 
or even induce MDSC suppressive activity it would demonstrate a novel role for IL-12 in 
modulating MDSC and therefore immune activation during cancer progression.  
 
In order to determine whether IL-12 could directly affect MDSC activity, MDSC were 
sorted and pretreated with 10 ng/ml recombinant mouse IL-12 for 24 hours at 37°C. 
Cells were washed and co-cultured with CFSE stained whole splenocytes and 
stimulated with 5 μg/ml anti-CD3 and anti-CD28 antibodies for 4 days. Whole 
splenocytes were also pretreated with IL-12 for 24 hours and co-cultured with MDSC 
and stimulated with anti-CD3 and anti-CD28 antibodies as a control. Cells were 
harvested and stained with fluorochrome-conjugated anti-CD4 antibody and gated 
during analysis for CD4+ T Cells. Cell activation was determined by CFSE dilution of 
CD4+ T cells via flow cytometry. 
 
As figures 8 and 9 demonstrate, pretreatment of whole splenocytes with IL-12 does not 
alter the ability of MDSC to suppress T cell activation with as few as 1 percent of the 
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cells capable of being activated (Figures 8 D and 9 D). This was equivalent to the levels 
of suppression exhibited by the untreated MDSC control (Figures 8 C and 9 C). MDSC 
pretreated with IL-12 for 24 hours, however, lose the ability to suppress T cell activation 
even at the strong 1:1 ratio (Figures 8 D and E and 9 D and E). As much as 65 percent 
of the T cells were activated following pretreatment of MDSC with IL-12. The loss of 
suppressive function is seen in both spleen-derived and tumor-derived MDSC (Figures 8 
E and F and 9 E and F, respectively). This finding was not mouse strain-specific as the 
loss in suppressive function was observed in both C3H/HeJ (Figure 8) and Balb/c 
(Figure 9) mouse strains. This loss in suppressive function when MDSC are pretreated 
with IL-12 is an impressive indication that IL-12 not only can act directly on MDSC but 
that it also alters the activity of the cells.  
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Figure 8. IL-12 
alters the 
suppressive 
activity of 
C3H/HeJ 
MDSC. 
C3H/HeJ naive 
whole 
splenocytes 
were stained 
with 10 μM 
CFSE and co-
cultured with 
C3H/HeJ 
MDSC sorted 
from digested 
tumors and 
spleens of 
C3L5 tumor-
bearing 
animals. MDSC 
were pretreated with or without 10 ng/ml IL-12 for 24 hours. Cells were then co-cultured 
in 96 well plates at a 1:1 ratio of whole splenocytes to MDSC for a total of 2 x 105 cells 
per well stimulated with anti-CD3 and anti-CD28 antibodies for 4 days. After the 4 day 
incubation, cells were stained with fluorochrome-conjugated anti-CD4 and anti-Gr-1 to 
isolate only the CD4+ T cells for analysis. Using gating and flow cytometric analysis, 
CD4+ T cells from untreated cells (negative control) (A) positive control anti-CD-3 and 
anti-CD-28 treated cells (B) and untreated MDSC control (C) were compared to CD4+ T 
cells pretreated with IL-12 prior to co-culture with untreated MDSC  (D) CD4+ T cells co-
cultured with IL-12 pretreated spleen-derived MDSC (E) and IL-12 pretreated tumor-
derived MDSC (F). Percentages indicate percent activation. 
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Figure 9. IL-12 
alters the 
suppressive 
activity of 
Balb/c MDSC. 
Balb/c naive 
whole 
splenocytes 
were stained 
and cultured as 
described 
previously 
(Figure 7). 
Using gating 
and flow 
cytometric 
analysis, CD4+ 
T cells from 
untreated cells 
(negative 
control) (A) 
positive control anti-CD-3 and anti-CD-28 antibody treated cells (B) and untreated 
MDSC control (C) were compared to CD4+ T cells pretreated with IL-12 prior to co-
culture with MDSC (D) CD4+ T cells co-cultured with IL-12 pretreated spleen-derived 
MDSC (E) and IL-12 pretreated tumor-derived MDSC (F). Percentages indicate percent 
activation. 
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IL-12 induces MDSC up-regulation of maturation markers in vitro 
It is clear from the data thus far that treatment of MDSC with IL-12 alters the suppressive 
function of the cells. The mechanism through which IL-12 alters MDSC activity remains 
to be determined. In order to assess how MDSC change following IL-12 treatment, 
several stains for surface markers were performed and analyzed. It has been proposed 
that Gr-1/CD11b double positive cells can be induced to mature into dendritic cells (DC) 
or macrophages, so we focused on markers known to be up-regulated on mature DC 
and macrophages: CD80, CD86, F4/80, and major histocompatibility complex class II 
(MHCII) (270). Up-regulation of these markers on MDSC could indicate a phenotypic 
change, that when coupled with the change in suppressive function, would indicate 
potential maturation. Comparisons between the functionally suppressive MDSC and 
naïve Gr-1/CD11b double positive cells were also performed. 
 
The flow cytometric analysis for changes in surface marker expression for naïve 
untreated and IL-12 treated Gr-1/CD11b double positive cells for C3H/HeJ and Balb/c 
murine models are outlined in figures 10 and 12, respectively. The flow cytometry 
analysis for spleen-derived and tumor-derived MDSC before and after IL-12 treatment is 
represented in figures 11 and 13. The changes in expression are summarized in table 2. 
 
The data show that Gr-1/CD11b double positive cells from naïve animals already 
express maturation markers for DC and Macrophages, supporting the findings that these 
cells are not only functionally but also phenotypically distinct from MDSC (Figures 10 
and 12; Table 2). Spleen-derived and tumor-derived MDSC do not express the DC and 
macrophage maturation markers prior to treatment with IL-12 (Figures 11 and 13; Table 
2). This distinguishes MDSC from general Gr-1/CD11b double positive cells and 
potentially from other macrophage types especially in the tumor microenvironment. The 
MDSC studied in this dissertation do express CD11b but do not express F4/80 unlike 
previously studied MDSC populations indicating that using CD11b as the sole marker for 
MDSC in previous studies did not evaluate at least one subpopulation of the MDSC 
populations present in the tumor.  
 
Following IL-12 treatment all markers were found to increase on the surface of spleen-
derived MDSC (Figures 11 A, B, C, and D and 13 A, B, C, and D). This up-regulation of 
surface markers indicates that these cells are potentially capable of maturation into cells 
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such as DC and macrophages and that IL-12 might be capable of inducing that 
maturation. Tumor-derived MDSC are distinct from spleen-derived MDSC in terms of IL-
12 response. Upon stimulation with IL-12, tumor-derived MDSC in vitro up-regulate only 
F4/80 and MHCII surface markers. Gr-1/CD11b double positive cells from naïve animals 
express several markers of mature cells and do not change the expression of these 
markers following treatment with IL-12. This data supports the definition of MDSC as a 
distinct population of cells from naïve Gr-1/CD11b double positive cells. 
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Figure 10. Surface marker expression of naïve C3H/HeJ Gr-1/CD11b double positive 
cells does not change following in vitro treatment with IL-12. Single cell suspensions of 
naïve splenocytes were stained with 2 μg/ml fluorochrome conjugated anti-Gr-1 and anti-
CD11b antibodies and sorted via flow cytometry. Sorted double positive cells were 
treated with 10 ng/ml recombinant mouse IL-12 for 24 hours. Cells were stained with 2 
μg/ml fluorochrome-conjugated anti-IgG, anti-CD80 (A), anti-F4/80 (B), anti-CD86 (C), 
and anti-MHCII (D) antibodies. Surface expression of the marker was determined by flow 
cytometry. Histogram analysis of whole splenocyte positive controls (green line), IgG 
stained as negative controls (black line), untreated Gr-1/CD11b double positive cells 
(blue line) and IL-12 treated Gr-1/CD11b double positive cells (red line) are shown. 
Results are summarized in table 2.  
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Figure 11. Changes in 
surface marker 
expression following in 
vitro treatment of Gr-
1/CD11b double positive 
cells derived from spleen 
and tumor of C3H/HeJ 
C3L5 tumor-bearing 
animals with IL-12. Single 
cell suspensions of 
spleens and tumors from 
tumor-bearing animals 
were obtained and 
stained with 2 μg/ml 
fluorochrome conjugated 
anti-Gr-1 and anti-CD11b 
antibodies and sorted via 
flow cytometry. Sorted 
double positive cells were 
treated with 10 ng/ml 
recombinant mouse IL-12 
for 24 hours. Cells were 
stained with 2 μg/ml 
fluorochrome-conjugated 
anti-IgG, anti-CD80, anti-
F4/80, anti-CD86, and 
anti-MHCII antibodies. 
Surface expression of the 
marker was determined 
by flow cytometry. 
Histograms representing 
the analysis of 3 experiments stained for the expression of CD80 on spleen-derived (A) 
and tumor-derived (E), F4/80 on spleen-derived (B) and tumor-derived (F). CD86 on 
spleen-derived (C) and tumor-derived (G), and MHCII for spleen derived (D) and tumor-
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derived (H) Gr-1/CD11b double positive cells are shown. The histogram analysis 
includes expression of each marker on the surface of positive controls (green line), IgG 
stained negative controls (black line), untreated MDSC (blue line) and IL-12 treated 
MDSC (red line). Results are summarized in table 2. 
 
 
 
Figure 12. Surface marker expression of naïve Balb/c Gr-1/CD11b double positive cells 
does not change following in vitro treatment with IL-12. Cells were sorted and stained as 
described previously (Figure 9). Results of staining with anti-CD80 (A), anti-F4/80 (B), 
anti-CD86 (C), and anti-MHCII (D) antibodies are shown. Histogram analysis of whole 
splenocyte positive controls (green line), IgG stained as negative controls (black line), 
untreated Gr-1/CD11b double positive cells (blue line) and IL-12 treated Gr-1/CD11b 
double positive cells (red line). Results are summarized in table 2. 
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Figure 13. Changes in 
surface marker expression 
following in vitro treatment 
of Gr-1/CD11b double 
positive cells derived from 
spleen and tumor of Balb/c 
4T1 tumor-bearing animals 
with IL-12. Cells were 
stained as described 
previously (Figure 10). 
Histograms representing 
the results of 3 
experiments stained for the 
expression of CD80 on 
spleen-derived (A) and 
tumor-derived (E), F4/80 
on spleen-derived (B) and 
tumor-derived (F). CD86 
on spleen-derived (C) and 
tumor-derived (G), and 
MHCII for spleen derived 
(D) and tumor-derived (H) 
Gr-1/CD11b double 
positive cells are shown. 
The histogram analysis 
includes expression of 
each marker on the surface 
of whole splenocyte 
positive controls (green 
line), IgG stained negative 
controls (black line), 
untreated MDSC (blue line) and IL-12 treated MDSC (red line). Results are summarized 
in table 2. 
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Table 2. Summary of the expression of surface markers after in vitro analysis. In this 
table, (-) designates not expressed, (+) designates expressed at levels below positive 
controls, (++) designates expressed at levels equal to positive controls, and (+++) 
designates expressed at levels exceeding positive controls. 
 
 
IL-12 treatment reduces the expression of Nos2, IFN-γ and ArgI mRNA in MDSC  
Although this up-regulation of maturation markers is sufficient to demonstrate and begin 
to define a change on MDSC induced by IL-12, how that change is actually correlated 
with the loss of suppressive function needs to be determined. It is known that one of the 
critical mechanisms for MDSC suppressive activity is the production of reactive nitrogen 
species mediated by the expression of nitric oxide synthases such as Nos2. Reductions 
in Nos2 mRNA and protein have been shown to correlate to a reduction in suppressive 
activity both in vitro and in vivo (271). In addition to studying Nos2, it can be essential to 
study regulation of Nos2 to better define the effects of a given treatment. Nos2 is 
inducible by IFN-γ expression regardless of whether it is utilized from intracellular 
production or extracellular sources. Studies performed on MDSC after IL-12 treatment 
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using ELISA did not indicate any extracellular IFN-γ production (data not shown); 
however, it is possible that all of the cytokine was produced and utilized internally. In 
order to define whether changes in Nos2 and IFN-γ may be playing a role in these cells, 
RNA was extracted and mRNA levels analyzed using real-time polymerase chain 
reaction (PCR). Figure 14 represents relative Nos2 mRNA while figure 15 represents 
relative IFN-γ mRNA. The figures demonstrate levels of expression as normalized and 
compared to naïve Gr-1/CD11b double positive and graphed as a fold change. C3H/HeJ 
derived cells (Figures 14 A and 15 A) and Balb/c derived cells (Figures 14 B and 15 B) 
are representative of 3 individual experiments and real-time PCR assays. 
 
Expression of Nos2 and IFN-γ mRNA were increased in MDSC compared to Gr-
1/CD11b double positive cells from naïve animals regardless of tissue type. The levels of 
Nos2 and IFN-γ expressed by tumor-derived MDSC were, however, higher than the 
levels expressed in spleen-derived MDSC. Tumor-derived MDSC from C3H/HeJ animals 
exhibited up to 4 fold increase in Nos2 and 18 fold increase in IFN-γ mRNA expression 
over that from naïve Gr-1/CD11b double positive cells (Figures 14 A and 15 A). This is 
compared to approximately 1.5 fold and 4 fold increase over the expression in naïve 
cells for the spleen-derived MDSC. The levels for Balb/c animals were slightly lower than 
C3H/HeJ with tumor-derived cells exhibiting 2.5 fold and 4 fold increases over the 
expression in naïve cells of Nos2 and IFN-γ, respectively. Spleen-derived MDSC from 
Balb/c animals exhibit approximately 1.5 fold increases in Nos2 and slightly less than 1.5 
fold in IFN-γ (Figures 14 and 15 B). Lower levels of IFN-γ expression in the spleen-
derived MDSC may account for differences in ability to differentiate in response to IL-12 
in vitro and is evidence that these cells may be distinct cells with potentially different 
activity than their tumor-derived associates in terms of overall suppressive activity in 
vivo. It is essential to note that the finding that both spleen-derived and tumor-derived 
cells expressed Nos2 at levels exceeding the naïve Gr-1/CD11b double positive controls 
supports the in vitro evidence of suppressive function for both cell types.  
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Figure 14. In vitro treatment with IL-12 reduces Nos2 mRNA expression. Gr-1/CD11b 
double positive cells were stained using fluorochrome-conjugated antibodies and sorted 
from the spleens of naïve animals as well as the spleens and tumors of tumor-bearing 
animals. Sorted MDSC were treated for 24 hours with 10 ng/ml recombinant mouse IL-
12. RNA was extracted from sorted cell populations, converted to cDNA and analyzed 
for mRNA expression via Real Time PCR. The expression levels for Nos2 were 
normalized to expression from naïve double-positive cells and graphed as a fold change. 
The expression of Nos2 in C3H/HeJ (A) and Balb/c (B) are shown. Statistically 
significant reductions in mRNA expression were observed following treatment with IL-12 
(n = 9; *p < 0.05; ***p < 0.001).  
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Figure 15. In vitro treatment with IL-12 reduces IFN-γ mRNA expression. Cells were 
stained and RNA extracted as described previously (Figure 14). The expression levels 
for IFN-γ were normalized to the expression levels from naïve double-positive cells and 
graphed as a fold change. The expression of IFN-γ in C3H/HeJ (A) and Balb/c (B) are 
shown. Statistically significant reductions in mRNA expression were observed following 
treatment with IL-12 (n = 9; *p < 0.05; ***p < 0.001). 
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In addition to Nos2, arginase expression in MDSC mediated by mRNA expression of 
Arg1 is also responsible for conferring the suppressive activity of MDSC. Reductions in 
ArgI have been shown to abrogate the suppressive effects of MDSC (272). It has been 
suggested that in order to reverse suppressive function, treatment must induce a 
reduction in both Nos and ArgI. In order to determine whether arginase was also 
involved in conferring suppressive function, I analyzed mRNA expression of ArgI in Gr-
1/CD11b double positive cells and MDSC. Figure 16 represents mRNA expression of 
ArgI normalized and compared to naïve Gr-1/CD11b double positive cells. 
 
The pattern of mRNA expression for ArgI mRNA in both C3H/HeJ derived cells (A) and 
Balb/c derived cells (B) was similar to the pattern of expression for both Nos2 and IFN-γ 
mRNA. ArgI was increased in both tumor-derived and spleen-derived MDSC compared 
to naïve Gr-1/CD11b double positive cells. ArgI expression was present in both spleen-
derived and tumor-derived MDSC with approximately 3 fold increases in tumor derived 
MDSC and 2.5 fold increases in spleen-derived MDSC above mRNA levels in naïve Gr-
1/CD11b double positive cells from C3H/HeJ animals (Figure 16 A). Higher levels of ArgI 
expression were found in Balb/c MDSC with approximately 8 fold higher levels and 4 fold 
higher levels of mRNA expression above naïve Gr-1/CD11b double positive cells for 
tumor-derived and spleen-derived MDSC, respectively.  
 
Treatment with IL-12 was found to significantly reduce ArgI expression in both the 
spleen-derived and tumor-derived MDSC. IL-12 altered ArgI mRNA expression to levels 
approximately equal to the levels in naïve Gr-1/CD11b double positive control cells. The 
positive finding of ArgI mRNA expression in the spleen-derived MDSC also supports the 
results that these are functionally suppressive cells. Although similar expression patterns 
were found, these ArgI studies indicate a key difference between the C3H/HeJ and 
Balb/c derived MDSC in vitro. C3H/HeJ derived MDSC exhibit higher levels of Nos2 
expression while Balb/c derived MDSC exhibit higher levels of ArgI expression. This 
reciprocal difference in expression levels could be representative of the differences in 
cell types that comprise the MDSC of these two murine models but further 
experimentation is required to define how distinct subpopulations may differ in terms of 
response to IL-12.  
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Figure 16. In vitro treatment with IL-12 reduces ArgI mRNA expression. Cells were 
isolated and RNA extracted as described previously (Figure 14). The expression levels 
for ArgI were normalized to the expression levels from naïve double-positive cells and 
graphed as a fold change. The expression of ArgI in C3H/HeJ (A) and Balb/c (B) IL-12 
treated and untreated Gr-1/CD11b double positive cells from spleens of both naïve and 
tumor-bearing animals as well as tumor-derived cells are shown. (n = 9; **p < 0.01; ***p 
< 0.001). 
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In vitro treatment with IL-12 reduced intracellular IFN-γ in MDSC 
In order to confirm that reduction in IFN-γ mRNA expression following in vitro IL-12 
treatment correlates with a reduction in IFN-γ cytokine levels, the expression of 
intracellular IFN-γ was determined. As discussed previously, much of the IFN-γ required 
for the suppressive function of these cells is expressed internally. Decreases in the 
protein level serve as an indicator that the reductions in IFN-γ mRNA observed in these 
studies have physiological relevance to the suppressive function of the MDSC. 
 
Sorted Gr-1/CD11b double positive cells from naïve and tumor bearing C3H/HeJ (A) and 
Balb/c (B) animals were studied following 24 hours in vitro treatment with IL-12 (Figure 
17). Approximately 65 percent of the tumor-derived MDSC and 45 percent of the spleen-
derived MDSC from C3H/HeJ animals exhibited IFN-γ intracellular cytokine expression 
(Figure 17 A). The percentage of MDSC expressing intracellular IFN-γ in Balb/c animals 
was slightly lower than in C3H/HeJ with approximately 50 percent of the tumor-derived 
MDSC and 35 percent of the spleen-derived MDSC testing positive (Figure 17 B). 
Treatment with IL-12 was found to significantly reduce the percentage of cells that 
express intracellular IFN-γ. IL-12 reduced IFN-γ expression to levels at or below naïve 
cells for both models. This is regardless of whether the cells were derived from the 
tumors or spleens of the animals. This confirmation of the mRNA results emphasizes the 
importance of IFN-γ in these cells and is consistent with findings that IFN-γ priming is 
critical to MDSC suppressive function.  
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Figure 17. In vitro treatment with IL-12 reduces IFN-γ protein expression in MDSC. Gr-
1/CD11b double positive cells were stained using 2 μg/ml fluorochrome-conjugated 
antibodies and sorted from the spleens of naïve animals as well as the spleens and 
tumors of tumor-bearing animals. Sorted MDSC were treated for 24 hours with 10 ng/ml 
recombinant mouse IL-12. Cells were then permeabilized and stained using 2 μg/ml 
fluorochrome-conjugated anti-IFN-γ antibody. The expression of IFN-γ in C3H/HeJ (A) 
and Balb/c (B) IL-12 treated and untreated Gr-1/CD11b double positive cells from 
spleens of both naïve and tumor-bearing animals as well as tumor-derived cells are 
shown. Results represent 3 individual experiments stained in triplicate (n = 9; *p < 0.05; 
**p < 0.01; ***p < 0.001). 
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IL-12 reduces IL-10 production and increases TNF-α production predominantly 
from tumor-derived MDSC 
Although the expression pattern of the surface markers of the tumor-derived MDSC 
defined in this dissertation are not equivalent to those expected for macrophages, the 
fact that MDSC have been shown to potentially function as macrophages in other 
studies means that further characterization of the cells in these studies is necessary to 
fully define their activity. Tumor-infiltrating macrophages are associated with the 
potential to be either activating (M1) or suppressive (M2) (273-276). Although there are 
limitations in the studies that determined MDSC could behave as suppressive 
macrophages, the similarities between the two populations is enough to suggest a 
possibility for similar cytokine activity (277). MDSC have been shown to express  IL-10 
while depleting IL-12 from macrophages, therefore the potential role for IL-12 on MDSC 
cytokine production needs to be defined (278). Since suppressive MDSC and M2 
macrophages in the tumor microenvironment are known to express IL-10 while M1 
activating macrophages express TNF-α, we determined the expression pattern for both 
of these molecules with and without treatment of IL-12 for 24 hours.  
 
Gr-1/CD11b double positive cells from naïve animals and MDSC from tumor-bearing 
animals were sorted and treated with IL-12 for 24 hours. Cell conditioned media was 
harvested for analysis of protein expression while RNA was extracted from the cells for 
analysis of mRNA expression. mRNA expression for IL-10 (Figure 18) and TNF-α 
(Figure 20)  was determined via quantitative real-time PCR while IL-10 (Figure 19) and 
TNF-α (Figure 21)  protein concentration was determined via ELISA.  
 
MDSC were found to express IL-10 mRNA and protein both of which were significantly 
reduced following treatment with IL-12. IL-10 mRNA expression was approximately 7.5 
to 9 fold higher in tumor-derived MDSC compared to naïve Gr-1/CD11b cells for both 
Balb/c animals (Figure 18 B) and C3H/HeJ animals (Figure 18 A), respectively. Spleen-
derived MDSC express 3 to 5 fold higher levels of expression of IL-10 mRNA over naïve 
Gr-1/CD11b double positive cells for Balb/c (Figure 18 B) and C3H/HeJ animals (Figure 
18 A). Protein expression from both tumor-derived cells compared to spleen-derived 
cells was increased compared to naïve cells though they were not significantly different 
from each other for the 24 hour in vitro study regardless of whether they were from 
C3H/HeJ animals (Figure 19 A) or Balb/c animals (Figure 19 B). MDSC were found to 
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express higher levels of IL-10 protein which was significantly decreased following 
treatment with IL-12 for both tissue types and models (Figure 19).  
 
The opposite pattern of expression from IL-10 was observed for TNF-α. Expression of 
TNF-α mRNA and protein was found to significantly increase following treatment with IL-
12. MDSC from tumor and spleen express similar levels of TNF-α as naïve Gr-1/CD11b 
double positive cells; however, following treatment with IL-12 significant increases in 
TNF-α mRNA and protein were observed for both C3H/HeJ (Figures 20 A and 21 A) and 
Balb/c (Figures 20 B and 21 B). This was true for both tumor-derived and spleen-derived 
MDSC. These findings indicate potential similarities exist between the cytokine profile of 
the MDSC analyzed in these studies and suppressive M2 macrophages. Following 
treatment with IL-12, the cytokine profile of the MDSC analyzed in these studies 
changes to resemble at least one of the cytokines important in M1 activating 
macrophages. 
 
 
 
Figure 18. In vitro treatment with IL-12 reduces IL-10 mRNA expression. Cells were 
isolated and RNA extracted as described previously (Figure 14). The expression levels 
for IL-10 were normalized to the expression levels from naïve double-positive cells and 
graphed as a fold change. The expression of IL-10 in C3H/HeJ (A) and Balb/c (B) IL-12 
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treated and untreated Gr-1/CD11b double positive cells from spleens of both naïve and 
tumor-bearing animals as well as tumor-derived cells are shown. (n = 9; ***p < 0.001). 
 
 
 
Figure 19. In vitro treatment with IL-12 reduces IL-10 protein expression from MDSC. 
Gr-1/CD11b double positive cells were stained using fluorochrome-conjugated 
antibodies and sorted from the spleens of naïve animals as well as the spleens and 
tumors of tumor-bearing animals. 1 x 106 sorted MDSC were incubated alone or with 10 
ng/ml recombinant mouse IL-12 for 24 hours. Media was harvested and analyzed for the 
expression of cytokine via ELISA. The expression of IL-10 in C3H/HeJ (A) and Balb/c (B) 
IL-12 treated and untreated Gr-1/CD11b double positive cells from spleens of both naïve 
and tumor-bearing animals as well as tumor-derived cells are shown (pg/ml). (n = 9; ***p 
< 0.001). 
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Figure 20. In vitro treatment with IL-12 induces TNF-α mRNA expression. Cells were 
stained and RNA extracted as described previously (Figure 14). The expression levels 
for TNF-α were normalized to the expression levels from naïve double-positive cells and 
graphed as a fold change. The expression of TNF-α in C3H/HeJ (A) and Balb/c (B) IL-12 
treated and untreated Gr-1/CD11b double positive cells from spleens of both naïve and 
tumor-bearing animals as well as tumor-derived cells are shown. (n = 9; *p < 0.05; ***p < 
0.001). 
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Figure 21. In vitro treatment with IL-12 induces TNF-α protein expression from MDSC. 
Cells were obtained and treated as described previously (Figure 19). The expression of 
TNF-α in C3H/HeJ (A) and Balb/c (B) IL-12 treated and untreated Gr-1/CD11b double 
positive cells from spleens of both naïve and tumor-bearing animals as well as tumor-
derived cells are shown (pg/ml). (n = 9; *p < 0.05). 
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IL-12 induces MDSC up-regulation of maturation markers in vivo 
In order to determine whether all of these results correlate with an in vivo response to IL-
12 treatment, analysis of in vivo treated cells was performed. C3L5 and 4T1 tumors were 
generated in the mammary fat pads of C3H/HeJ and Balb/c animals respectively. Once 
tumors grew to an average of 300 mm3, intramuscular injections with adenovirus 
expressing either luciferase or recombinant IL-12 were performed. Twenty-four hours 
after injection, tumors and spleens were harvested and single cells suspensions 
obtained for further analysis. Serum analysis was used to confirm IL-12 expression. 
Figure 22 represents IL-12 expression prior to and following treatment with the viruses. 
Only animals treated with adenovirus expressing recombinant IL-12 demonstrated a 
systemic increase in IL-12 expression. These expression levels on the average were 
similar to the levels used in vitro though with considerably more variation than the in vitro 
studies.  
 
 
Figure 22. Serum IL-12 
expression 24 hours after 
injection with AdLuc or 
AdIL-12. C3H/HeJ and 
Balb/c animals were 
injected with 2.5 x 105 
C3L5 and 1 x 105 4T1 
cells respectively. Once 
tumors reached an 
average size of 300 mm3 
animals were 
intramuscularly injected 
with 1x 109 virus particles 
of recombinant 
adenovirus expressing a 
luciferase reporter gene (AdLuc) or recombinant mouse IL-12 (AdIL-12) (5 animals per 
group). Serum was harvested immediately prior to and 24 hours after injection for 
analysis of IL-12 expression. The concentration of IL-12 expressed in the serum of 
adenovirus-treated animals was determined via ELISA.  
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Using identical staining protocols as those used for the in vitro studies, treatment with IL-
12 was found to be capable of altering the expression of all 4 markers studied regardless 
of whether they were spleen-derived or tumor-derived MDSC (Table 3). The ability to 
see changes in CD80 and CD86 expression for the tumor-derived cells in vivo indicates 
a discrepancy between treatments that can be explained by the additional in vivo cellular 
interactions. It is possible that there may be alterations of the cells caused by in vitro 
culturing but it is more probable that the presence of other cells capable of responding to 
IL-12 altered the overall effects of the treatment. For example, T cells can have co-
stimulatory effects on macrophages and dendritic cells and they also respond to IL-12 
when previously activated by antigen. It is probable that IL-12 is acting not only on the 
MDSC but also on stimulated T cells to promote further maturation and proinflammatory 
activation of the MDSC. 
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Figure 23. In vivo 
treatment with AdIL-12 
results in the up-regulation 
of surface markers on 
C3H/HeJ C3L5 tumor-
bearing animals spleen- 
and tumor-derived Gr-
1/CD11b double positive 
cells. C3H/HeJ animals 
were injected with 2.5 x 
105 C3L5 cells. Once 
tumors reached an 
average size of 300 mm3 
the animals were 
intramuscularly injected 
with 1x 109 virus particles 
of recombinant adenovirus 
expressing a luciferase 
reporter gene (AdLuc) or 
IL-12 (AdIL-12) (5 animals 
per group). 24 hours after 
the injection animals were 
euthanized and tissues 
were harvested for further 
analysis. Single cell 
suspensions of spleens 
and tumors from 
adenovirus-treated tumor-
bearing animals were 
obtained. Cells were 
stained with 2 μg/ml 
fluorochrome-conjugated anti-IgG, anti-Gr-1, anti-CD80, anti-F4/80, anti-CD86, and anti-
MHCII antibodies. Surface expression of the marker was determined by flow cytometry. 
Histograms representing triplicate staining for the expression of CD80 on spleen-derived 
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(A) and tumor-derived (E), F4/80 on spleen-derived (B) and tumor-derived (F). CD86 on 
spleen-derived (C) and tumor-derived (G), and MHCII for spleen derived (D) and tumor-
derived (H) Gr-1/CD11b double positive cells are shown. The histogram analysis 
includes expression of each marker on the surface of whole splenocyte positive controls 
(green line), IgG stained negative controls (black line), AdLuc treated Gr-1/CD11b 
double positive cells (blue line) and AdIL-12 treated Gr-1/CD11b double positive cells 
(red line). The graphs are representative of three individual experiments performed in 
triplicate (n = 9). Results are summarized in table 3. 
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Figure 24. In vivo 
treatment with AdIL-12 
results in the up-
regulation of surface 
markers on Balb/c 4T1 
tumor-bearing animals 
spleen- and tumor-
derived Gr-1/CD11b 
double positive cells. 
Balb/c animals were 
injected with 1 x 105 4T1 
cells. Animals were 
treated and cells 
harvested as described 
previously (Figure 22). 
Cells were stained with 2 
μg/ml fluorochrome-
conjugated anti-IgG, anti-
Gr-1, anti-CD80, anti-
F4/80, anti-CD86, and 
anti-MHCII antibodies. 
Surface expression of the 
marker was determined 
by flow cytometry. 
Histograms representing 
triplicate staining for the 
expression of CD80 on 
spleen-derived (A) and 
tumor-derived (E), F4/80 
on spleen-derived (B) 
and tumor-derived (F). 
CD86 on spleen-derived (C) and tumor-derived (G), and MHCII for spleen derived (D) 
and tumor-derived (H) Gr-1/CD11b double positive cells are shown. The histogram 
analysis includes expression of each marker on the surface of whole splenocyte positive 
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controls (green line), IgG stained negative controls (black line), AdLuc treated Gr-
1/CD11b double positive cells (blue line) and AdIL-12 treated Gr-1/CD11b double 
positive cells (red line). The graphs are representative of three individual experiments 
performed in triplicate (n = 9). Results are summarized in table 3. 
 
 
 
Table 3. Summary of the expression of surface markers following in vivo analysis. In this 
table, (-) designates not expressed, (+) designates expressed at levels below positive 
controls, (++) designates expressed at levels equal to positive controls, and (+++) 
designates expressed at levels exceeding positive controls. 
 
 
In vivo AdIL-12 treatment reduces the expression of Nos2, ArgI, and IFN-γ mRNA 
in MDSC 
In order to confirm whether the other significant internal changes in MDSC can be 
replicated in vivo, MDSC from AdLuc and AdIL-12 treated animals as well as Gr-
1/CD11b double positive cells from naïve animals were sorted using the same protocols 
for the in vitro studies. Following RNA extraction and conversion into cDNA, quantitative 
real-time PCR analysis was performed. 
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The expression of Nos2 (Figure 25), IFN-γ (Figure 26), and ArgI (Figure 27) mRNA were 
found to be significantly higher in MDSC compared to naïve Gr-1/CD11b double positive 
cells. The mRNA for all three molecules was found to decrease following in vivo 
treatment with AdIL-12. The expression patterns were consistent with the in vitro studies 
though the fold increase in MDSC expression of Nos2 and IFN-γ mRNA above that of 
naïve Gr-1/CD11b double positive cells was found to be higher in vivo for the Balb/c 
animals  than in the in vitro studies (Figures 25 B and 26 B). Balb/c tumor-derived MDSC 
exhibit approximately 9 fold higher expression of Nos2, 20 fold higher expression of IFN-
γ and 8 fold higher expression of ArgI than naïve Gr-1/CD11b double positive cells 
(Figures 25 B, 26 B and 27 B). C3H/HeJ tumor-derived MDSC and spleen derived 
exhibit comparable levels of mRNA in vitro and in vivo with the in vivo studies indicating 
approximately 4 fold and 1.5 higher expression of Nos2, roughly 15 fold and 3 fold 
higher expression of IFN-γ and, 3 fold and 2.5 fold higher expression of ArgI compared 
to naïve Gr-1/CD11b double positive cells (Figures 25 A, 26 A, and 27A). The changes 
in mRNA and surface marker expression observed in both the tumor-derived and 
spleen-derived MDSC harvested from the AdIL-12 treated animals implies a systemic 
effect of IL-12 is possible in cases of intramuscular injection. This consistency between 
in vivo and in vitro treatment with IL-12 indicates a new role for IL-12 in terms of its 
ability to induce up-regulation of maturation markers on the surface of MDSC, decrease 
key regulators of MDSC activity, and modulate immune suppression.  
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Figure 25. In vivo treatment with AdIL-12 reduces Nos2 mRNA expression. C3H/HeJ 
and Balb/c tumor-bearing animals were treated with intramuscular injections of 1 x 109 
adenovirus particles of either AdLuc or AdIL-12. Twenty-four hours after inoculation with 
virus, tumors were harvested and digested to obtain single cell suspensions. Gr-
1/CD11b double positive cells were stained using fluorochrome-conjugated antibodies 
and sorted from the spleens and tumors of AdLuc or AdIL-12 treated animals. RNA was 
extracted from sorted cell populations, converted to cDNA and analyzed for mRNA 
expression via Real Time PCR. The expression levels for Nos2 and INF-γ were 
normalized to expression from naïve double-positive cells and graphed as a fold change. 
The expression of Nos2 in C3H/HeJ (A) and Balb/c (B) and expression of IFN-γ in 
C3H/HeJ (C) and Balb/c (D) are shown. Statistically significant reductions in mRNA 
expression were observed following treatment with IL-12 (*p < 0.05; ***p < 0.001). 
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Figure 26. In vivo treatment with AdIL-12 reduces IFN-γ mRNA expression. Cells were 
generated, isolated and RNA extracted as described previously (Figure 25). The 
expression of IFN-γ mRNA in C3H/HeJ (A) and Balb/c (B) Gr-1/CD11b double positive 
cells from spleens of both naïve and tumor-bearing animals as well as tumor-derived 
cells are shown. Statistically significant reductions in mRNA expression were observed 
following treatment with IL-12 (***p < 0.001). 
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Figure 27. In vivo treatment with AdIL-12 reduces ArgI mRNA expression. Cells were 
generated, isolated and RNA extracted as described previously (Figure 25). The 
expression of ArgI mRNA in C3H/HeJ (A) and Balb/c (B) Gr-1/CD11b double positive 
cells from spleens of both naïve and tumor-bearing animals as well as tumor-derived 
cells are shown. Statistically significant reductions in mRNA expression were observed 
following treatment with IL-12 (***p < 0.001). 
 
 
In vivo AdIL-12 treatment reduces IL-10 production and increases TNF-α 
production predominantly from tumor-derived MDSC 
In order to continue to define the role that in vivo treatment of MDSC with IL-12 has on 
overall MDSC activity, we sought to determine whether the same M2 suppressive 
cytokine, IL-10, and M1 activating cytokine, TNF-α, were also altered following treatment 
with AdIL-12. Using the same experimental conditions as was used to study Nos2, IFN-
γ, and ArgI, we determined the changes in expression of IL-10 (Figure 28) and TNF-α 
(Figure 29) mRNA following treatment with AdIL-12. As expected from the in vitro 
results, MDSC isolated from tumor-bearing animals treated with AdIL-12 exhibited 
decreased expression of IL-10 mRNA and increased expression of TNF-α mRNA. This 
was regardless of whether the cells were isolated from C3H/HeJ (Figures 28 and 29 A) 
or Balb/c (Figures 28 and 29 B) treated animals.  
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C3H/HeJ MDSC animals treated with AdLuc were found to express 7 fold higher and 4 
fold higher levels of IL-10 in the tumor-derived and spleen-derived MDSC, respectively, 
which was reduced to the levels exhibited by naïve Gr-1/CD11b double positive cells if 
the cells received treatment with AdIL-12 (Figure 28 A). Balb/c AdLuc treated MDSC 
were found to exhibit 6 fold and 3 fold higher levels of IL-10 in tumor-derived and spleen-
derived MDSC, respectively (Figure 28 B). These levels were also reduced to the levels 
of expression for naïve Gr-1/Cd11b double positive cells following treatment with AdIL-
12. Similar to in vitro studies MDSC from AdLuc treated tumor-bearing animals did not 
express TNF-α at levels above those of naïve Gr-1/CD11b double positive cells 
regardless of tissue type or whether they were derived from C3H/HeJ (Figure 29 A) or 
Balb/c (Figure 29 B) animals. 
 
 
 
Figure 28. In vivo treatment with AdIL-12 reduces IL-10 mRNA expression. Cells were 
generated, isolated and RNA extracted as described previously (Figure 25). The 
expression of IL-10 mRNA in C3H/HeJ (A) and Balb/c (B) Gr-1/CD11b double positive 
cells from spleens of both naïve and tumor-bearing animals as well as tumor-derived 
cells are shown. Statistically significant reductions in mRNA expression were observed 
following treatment with IL-12 (***p < 0.001). 
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Figure 29. In vivo treatment with AdIL-12 induces TNF-α mRNA expression. Cells were 
generated, isolated and RNA extracted as described previously (Figure 25). The 
expression of TNF-α mRNA in C3H/HeJ (A) and Balb/c (B) Gr-1/CD11b double positive 
cells from spleens of both naïve and tumor-bearing animals as well as tumor-derived 
cells are shown. Statistically significant reductions in mRNA expression were observed 
following treatment with IL-12 (***p < 0.001). 
 
 
Treatment of C3L5 and 4T1 tumor-bearing animals with AdIL-12 results in a 
reduction in tumor growth and enhanced overall survival 
The studies performed thus far defined a new activity for IL-12 to act directly on immune 
suppressor cells altering their activity. These findings indicate that IL-12 reverses 
immune suppression which may permit immune activation in the tumor leading to 
suppression of tumor growth. In order to determine what effect the alteration of MDSC 
could have in terms of breast cancer therapeutics, we studied the anti-tumor therapeutic 
efficacy of treatment with AdIL-12. Throughout the in vitro and in vivo studies of the 
effects of IL-12, orthotopic murine breast cancer models were used to both generate the 
cells of interest and to study the in vivo effects on the MDSC. These models were 
generated by direct injection of the cells into mammary fat pads. In the previous in vivo 
studies, tumors were allowed to develop to above 300 mm3 so that there would be 
significant MDSC levels for analysis. In the following studies we were interested in 
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overall anti-tumor efficacy and long-term effects so tumors were injected at an average 
size of approximately 65 mm3.  
 
C3L5 and 4T1 tumor-bearing animals were treated with AdIL-12 or AdLuc via 
intramuscular injections of 1 x 109 virus particles per animal (10 animals per group). 
Serum was extracted immediately prior to injection with the virus as well as 24, 48, and 
72 hours after injection. One C3H/HeJ animal was lost due to overdose of ketamine prior 
to injection with virus and was eliminated from the study. Although the in vivo 
experiments were performed multiple times, there was a tendency to lose animals during 
serum extractions. Serum protein expression of both IL-12 and IFN-γ were determined 
via ELISA (Figure 30). Only AdIL-12 treated animals were found to express increased 
levels of IL-12 expression following injection with the recombinant adenovirus. This 
demonstrates that the expression of IL-12 is specific to the IL-12 expression cassette 
and not an effect of anti-viral immune activation.  
 
Expression of IL-12 was found to peak 24 hours after treatment with AdIL-12 and return 
to basal levels by 72 hours after treatment for both C3H/HeJ (Figure 30 A) and Balb/c 
(Figure 30 B) tumor-bearing animals. Expression of IFN-γ was not observed above basal 
levels until 72 hours after treatment for both C3H/HeJ (Figure 30 C) and Balb/c (Figure 
30 D) AdIL-12 treated, tumor-bearing animals. IFN-γ levels were found in past 
experiments to peak at 96 hours and return to basal levels by 7 days, though this was 
not determined for these experiments (data not shown). The levels of IL-12 from the in 
vivo experiments on the average were around the levels used for all the in vitro studies. 
It is important to note that these are relatively low levels compared to other IL-12 in vivo 
studies that quantified serum IL-12 levels described previously (224, 260-266). Analysis 
of animal weight over time and examination of livers did not indicate a significant 
difference between AdLuc and AdIL-12 treated animals (data not shown). This implies a 
decrease in risk of toxic side-effects from this adenovirus-mediated IL-12 expression 
compared to those observed following treatment with IL-12 in previously discussed 
studies. 
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Figure 30. AdIL-12 treatment induces serum expression of IL-12 and IFN-γ. C3H/HeJ 
and Balb/c animals were injected with 2.5 x 105 C3L5 and 1 x 105 4T1 cells respectively. 
Once tumors reached an average size of 65 mm3 animals were intramuscularly injected 
with 1x 109 virus particles of recombinant adenovirus expressing a luciferase reporter 
gene (AdLuc) or recombinant mouse IL-12 (AdIL-12) (9 or 10 animals per group). Serum 
was harvested immediately prior to injection as well as 24, 48 and 72 hours after 
injection for analysis of IL-12 and IFN-γ expression via ELISA. One C3H/HeJ animal 
received an accidental overdose prior to injection with AdIL-12 and was therefore 
eliminated from the study. The concentration of IL-12 expressed in the serum of 
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C3H/HeJ (A) and Balb/c (B) adenovirus-treated animals was determined via ELISA and 
is represented in ng/ml. The concentration of IFN-γ expressed in the serum of C3H/HeJ 
(C) and Balb/c (D) adenovirus-treated animals was also determined via ELISA and is 
represented in pg/ml. 
 
 
In order to determine whether this exogenous expression of IL-12 had an impact on 
tumor growth, tumors were measured twice weekly until they grew to a volume of 
approximately 500mm3. Tumor growth for C3H/HeJ C3L5 tumor-bearing animals are 
presented in figure 31 while tumor growth for Balb/c 4T1 tumor-bearing animals is 
presented in figure 32. Treatment with AdIL-12 was found to suppress tumor growth 
(Figures 31 and 32 B) with a significant increase in overall survival for both animal 
models studied (Figure 33). C3H/HeJ C3L5 tumor-bearing animals were found to have a 
better overall response to treatment with AdIL-12 including one animal that 
demonstrated complete tumor regression as evidenced by the normal appearance of the 
mammary fat pad (Figure 31 and Figure 33 A; data not shown). This difference in 
treatment response could be due to differences in overall aggressiveness of the C3L5 
tumors compared to the 4T1 tumors. The effects of treatment with AdIL-12 are specific 
to IL-12, as AdLuc treatment did not suppress tumor growth (Figure 31 A and Figure 32 
A). Overall, a single-dose, intramuscular treatment with AdIL-12 is capable of altering 
tumor growth leading to significant improvements in overall survival. Results are 
summarized in table 4. 
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Figure 31. C3L5 tumor growth following AdLuc and AdIL-12 treatment of C3H/H3J 
tumor-bearing animals. C3H/HeJ murine fat pads were injected with 2.5 x 105 C3L5 
cells. Once tumors reached an average size of 65 mm3 animals were intramuscularly 
injected with 1x 109 virus particles of recombinant adenovirus expressing a luciferase 
reporter gene (AdLuc) (A) or recombinant mouse IL-12 (AdIL-12) (B). Tumor growth was 
measured twice weekly. 
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Figure 32. 4T1 tumor growth following AdLuc and AdIL-12 treatment of Balb/c tumor-
bearing animals. Balb/c murine fat pads were injected with 1 x 105 4T1 cells. Once 
tumors reached an average size of 65 mm3 animals were intramuscularly injected with 
1x 109 virus particles of recombinant adenovirus expressing a luciferase reporter gene 
(AdLuc) (A) or recombinant mouse IL-12 (AdIL-12) (B) (10 animals per group). Tumor 
growth was measured twice weekly. 
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Figure 33. Overall survival of C3H/HeJ and Balb/c tumor-bearing animals following 
treatment with AdLuc and AdIL-12. C3H/HeJ (A) and Balb/c (B) animals in figure 31 and 
32, respectively, were analyzed for overall survival with tumor volumes of 500 mm3 as 
the endpoint and counted as deaths (no actual deaths occurred) (*p < 0.05). 
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Table 4. AdIL-12 alters tumor growth and improves overall survival. This table 
summarizes data in figures 31 and 32.  It indicates days after inoculation with C3L5 and 
4T1 cells in C3H/HeJ and Balb/c animals, respectively.  (NR designates no response; 
PR designates partial response; CR designates complete response) 
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Treatment with AdIL-12 results in a long-term increase in leukocyte infiltration into 
the tumor microenvironment compared to AdLuc treatment 
Treatment of tumor-bearing animals with AdIL-12 delayed tumor growth, but the 
mechanism of that delay and its relationship with alterations in immune suppression 
remain to be determined. The range of effect following treatment with AdIL-12 could be 
due to differences in IL-12 expression though these differences do not account for the 
large variations in tumor growth observed in C3H/HeJ C3L5 tumor-bearing animals. 
Although this study does not seek to answer this question directly, an inference can be 
made from observations of the changes in both the composition of lymphocytes in the 
tumor microenvironment and MDSC populations following treatment with AdIL-12.  
 
In order to determine whether treatment with AdIL-12 was altering the tumor 
microenvironment in general, histological analysis of tumor sections was performed. 
Tumors from AdLuc and AdIL-12 treatment groups were embedded as frozen tissue, 
sectioned, and attached to slides for histological analysis. General light microscopy was 
used to generate images of the tumor histology following staining procedures for 
visualization of structures. C3H/HeJ C3L5 AdLuc (Figure 34 A and B) and AdIL-12 
(Figure 34 C and D) treated tumors were analyzed. AdIL-12 treatment was found to 
exhibit an increase in leukocyte infiltration into the tumor compared to AdLuc controls. 
This finding was consistent with Balb/c 4T1 AdIL-12 treated tumors (Figure 35 C and D) 
compared to AdLuc treated tumors (Figure 35 A and B) as well. In order to quantify the 
results obtained from the analysis of tissue sections, single cell suspensions were 
obtained separately and cells were stained for the general hematopoietic cell marker, 
CD45. The percentage of CD45 positive cells infiltrating the tumor was found to increase 
following treatment with AdIL-12 for both tumor models (Figure 33 B and D; Figure 34 B 
and D). 
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Figure 34. C3H/HeJ C3L5 Tumor Histology. C3H/HeJ murine fat pads were injected 
with 2.5 x 105 C3L5 cells. Once tumors reached an average size of 65 mm3 animals 
were intramuscularly injected with 1x 109 virus particles of recombinant adenovirus 
expressing a luciferase reporter gene (AdLuc) (A 10X; B 20X) or recombinant mouse IL-
12 (AdIL-12) (C 10X; D 20X). Tumor growth was measured twice weekly. Once tumors 
reached a volume of approximately 500 mm3 animals were humanely euthanized and 
tissues were harvested. Tumors were cut into three sections with one section preserved 
in OTC embedding compound and frozen. A second portion was digested and single cell 
suspensions were obtained. The frozen sections were sectioned onto slides and stained 
with H & E for analysis of histology. From the digested portion of tumor, single cell 
suspensions were stained with fluorochrome-conjugated anti-CD45 antibody and 
analyzed via flow cytometry. Percentages represent average percent of tumor that is 
CD45 positive (representative of 9 or 10 animals). 
 
 
 79 
 
 
Figure 35. Balb/c 4T1Tumor Histology. Balb/c murine fat pads were injected with 1 x 105 
4T1 cells. Once tumors reached an average size of 65 mm3 animals were 
intramuscularly injected with 1x 109 virus particles of recombinant adenovirus expressing 
a luciferase reporter gene (AdLuc) (A 10X; B 20X) or recombinant mouse IL-12 (AdIL-
12) (C 10X; D 20X). Tumor growth was measured twice weekly. Once tumors reached a 
volume of approximately 500 mm3 animals were humanely euthanized and tissues were 
harvested and analyzed as described previously (Figure 34). Percentages represent 
average percent of tumor that is CD45 positive (representative of 10 animals). 
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IL-12 has long-term effects on MDSC levels in tumor-bearing animals 
Although a general change in tumor architecture and leukocyte infiltration was observed 
what correlation that has if any with MDSC alterations remains to be determined. Thus 
far, we have demonstrated that even in vivo treatment with IL-12 can affect MDSC, but 
what correlation those changes have if any with tumor growth suppression long-term 
remains to be defined. It has been established that reductions in MDSC directly correlate 
with long-term effects on the tumor microenvironment and an increase in infiltration with 
T cells (279). In order to define a relationship between AdIL-12 treatment, tumor growth 
suppression, and MDSC in our system, we isolated single cell suspensions from AdLuc 
and AdIL-12 treated tumors and analyzed them for Gr-1/CD11b double positive cell 
content at the end of the tumor growth study.  
 
Figure 36 represents the percentage of Gr-1/CD11b double positive cells in the tumor 
microenvironment as a percentage of CD45+ cells. CD45 can be used as a general 
marker for lymphocyte/myeloid populations and serves as a better indicator of cell 
infiltration than comparing the presence of cells as a percentage of the entire tumor. 
Treatment with AdIL-12 was found to have a significant effect on the percentage of 
tumor-associated Gr-1/CD11b double positive cells present in the tumor at the end of the 
study. C3H/HeJ C3L5 tumors (Figure 36 A) and Balb/c 4T1 tumors (Figure 36 B) were 
both found to exhibit decreased levels of tumor-infiltrating Gr-1/CD11b double positive 
cells. All tumors were harvested at approximately equal volumes so differences in size 
alone cannot account for the significant decrease in Gr-1/CD11b double positive cells. 
Treatment with AdIL-12 suppresses Gr-1/CD11b double positive populations but does 
not eliminate them. The retention of these cells in combination with the variations in IL-
12 expression could explain the variations in tumor growth suppression though analysis 
of their overall function against T cell activation is necessary to define this further. 
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Figure 36. Gr-1/CD11b double positive cells are suppressed long-term following 
treatment with AdIL-12. C3H/HeJ and Balb/c animals were inoculated with 2 x 105 C3L5 
and 1 x 105 4T1 cells, respectively. Once tumors reached an average size of 65 mm3, 
intramuscular injections of 1 x 109 adenovirus particles of AdLuc or AdIL-12 was 
performed. Once tumors reached a volume of 500 mm3, tissues were harvested and 
single cell suspensions obtained. Gr-1/CD11b double positive cells were stained as a set 
of CD45+ cells using fluorochrome conjugated anti-Gr-1, anti-CD11b and anti-CD45 
antibodies. The percentage of Gr-1/CD11b double positive cells in C3H/HeJ (A) and 
Balb/c (B) tumors as a percentage of CD45+ cells was determined. Statistically 
significant decreases in Gr-1/CD11b double positive cells were observed following 
treatment with AdIL-12 (*p < 0.05; **p < 0.01).  
 
 
Treatment with AdIL-12 results in an increase in activated CD8+ tumor-infiltrating 
T Cells 
In order to determine whether AdIL-12 treatment was having an impact not only on the 
type of cells that infiltrate the tumor but also the activity of the cells, the presence of 
tumor infiltrating CD8+ T cells as well as their expression of IFN-γ was determined. 
Single cell suspensions of digested tumors were stained with fluorochrome-conjugated 
antibodies and analyzed via flow cytometry as a percentage of CD45+ cells as described 
previously.  
 
 82 
 
Figure 37 represents the infiltration of CD8+ T cells into C3H/HeJ C3L5 tumors (A) and 
Balb/c 4T1 tumors (B). Significant increases in the infiltration of CD8+ T cells occurred 
only after treatment with AdIL-12. Treatment with AdLuc did not significantly increase the 
infiltration of CD8+ T cells indicating that this is a direct effect of IL-12. The expression of 
IL-12 returns to basal levels after only 72 hours so this is a long-term effect of brief IL-12 
expression. Since Gr-1/CD11b double positive cells were still observed in the tumors of 
the AdIL-12 treated animals, infiltration alone is not likely to be sufficient to promote 
immune activation long-term.  
 
In order to determine whether these cells were active at the tumor even weeks after 
treatment with AdIL-12, the expression of intracellular IFN-γ was determined. Figure 38 
represents the percentage of tumor infiltrating CD8+ cells that were also IFN-γ positive. 
The percentage of IFN-γ expressing, tumor infiltrating CD8+ T cells were increased long-
term following treatment with AdIL-12 for both C3H/HeJ C3L5 (A) and Balb/c 4T1 (B) 
tumor models. This long-term immune activation indicates a significant potential for 
treatment utilizing IL-12. Although the percentage of IFN-γ positive CD8+ T cells is 
increased in the AdLuc treated animals the total percentage of CD8+ T cells coupled 
with the relatively unaltered Gr-1/CD11b double positive cell populations makes this 
result indicating a potential virus effect less impressive in minimizes the effect of the 
adenovirus vector in terms of potential therapeutic consequences. 
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Figure 37. In vivo treatment with IL-12 increases CD8+ T Cell infiltration into the tumor 
microenvironment. C3H/HeJ and Balb/c animals were inoculated with 2 x 105 C3L5 and 
1 x 105 4T1 cells, respectively. Once tumors reached an average size of 65 mm3, 
intramuscular injections of 1 x 109 adenovirus particles of AdLuc or AdIL-12 was 
performed. Once tumors reached a volume of 500 mm3, tissues were harvested and 
single cell suspensions obtained. CD8+ T cells were stained using fluorochrome-
conjugated anti-CD8 and anti-CD45 antibodies and analyzed via flow cytometry. The 
percentage of CD8+ T cells in C3H/HeJ (A) and Balb/c (B) tumors are also shown. 
Statistically significant increases in CD8+ T cells were observed following treatment with 
AdIL-12 (**p < 0.01). 
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Figure 38. In vivo treatment with IL-12 increases the percentage of CD8+ T cells that 
also express IFN-γ in the tumor microenvironment. C3H/HeJ and Balb/c animals were 
inoculated with 2 x 105 C3L5 and 1 x 105 4T1 cells, respectively. Once tumors reached 
an average size of 65 mm3, intramuscular injections of 1 x 109 adenovirus particles of 
AdLuc or AdIL-12 was performed. Once tumors reached a volume of 500 mm3, tissues 
were harvested and single cell suspensions obtained. CD8+ T cells were stained using 
fluorochrome-conjugated anti-CD8 and anti-IFN-γ antibodies and analyzed via flow 
cytometry. The percentage of CD8+ T cells that also express IFN-γ in C3H/HeJ (A) and 
Balb/c (B) tumors are also shown. Statistically significant increases in active IFN-γ+ 
CD8+ T cells were observed following treatment with AdIL-12 (***p < 0.001). 
 
 
Treatment with AdIL-12 significantly reduces metastasis 
It has been well established that IL-12 has anti-angiogenic and anti-metastatic properties 
(242-245). In addition to direct IL-12-mediated effects on metastasis, changes to MDSC 
populations have been shown to reduce metastases (28, 145, 153, 280). Given that 
AdIL-12 treatment results in an increase in potentially active CD8+ T cells in the tumor 
microenvironment and a decrease in Gr-1/CD11b double positive cells, what other long-
term effects the therapy might have were of significant interest. Lungs from tumor-
bearing animals were harvested at the point of tumor harvest and stained using Bouin’s 
fixative. The number of metastases from untreated tumor-bearing animals as well as 
AdLuc and AdIL-12 treated animals was determined and is represented in figure 39. 
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Stained naïve and tumor-bearing C3H/HeJ lungs with metastases indicated are 
represented in 40.  
 
Treatment with AdIL-12 was found to significantly reduce the number of metastases in 
both C3H/HeJ C3L5 (Figure 39 A) and Balb/c 4T1 (Figure 39 B) tumor-bearing animals. 
In the C3H/HeJ model, no lung metastases were found following IL-12 treatment. This 
significant reduction in metastasis may be the consequence of treatment with IL-12 or it 
could be a consequence of altering the overall immune suppression of the tumors. 
Although reductions in metastases have been linked to the influx of active T cells, how 
those cells can be active in the presence of suppressive cells needs to be considered. 
This dissertation begins to define the role of IL-12 as both an immune activator and an 
agent that alters immune suppression.  In order to fully define the correlation between 
reversing immune suppression and promoting a T cell response in terms of reducing 
metastases, further experimentation is required. 
 
 
  
Figure 39. In vivo treatment with IL-12 decreases the number of metastases. C3H/HeJ 
and Balb/c animals’ mammary fat pads were inoculated with 2 x 105 C3L5 and 1 x 105 
4T1 cells, respectively. Once tumors reached an average size of 65 mm3, intramuscular 
injections of 1 x 109 adenovirus particles of AdLuc or AdIL-12 was performed. Once 
tumors reached a volume of 500 mm3, lungs were harvested for analysis of metastasis. 
Lungs were fixed in Bouin’s fixative and metastases were counted. Analysis of 
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metastases from C3H/HeJ (A) and Balb/c (B) are also shown. Statistically significant 
reductions in metastasis were observed following treatment with AdIL-12 (***p < 0.001). 
 
 
 
Figure 40. In vivo treatment with IL-12 decreases the number of lung metastases. 
C3H/HeJ animals’ mammary fat pads were inoculated with 2 x 105 C3L5 cells. Once 
tumors reached an average size of 65 mm3, intramuscular injections of 1 x 109 
adenovirus particles of AdLuc or AdIL-12 was performed. Once tumors reached a 
volume of 500 mm3, lungs were harvested for analysis of metastasis. Lungs were fixed 
in Bouin’s fixative and images captured (images are not to scale). Findings are 
summarized in figure 39. 
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Discussion 
 
MDSC are a population of cells of great interest to immunologists and cancer 
researchers alike. These cells have a wide range of impacts in terms of immune 
modulation, cancer progression, and metastasis. While MDSC are known as Gr-
1/CD11b double positive cells, not all cells expressing both of these markers are MDSC. 
In order to be classified as an MDSC the cell must be functionally suppressive; 
specifically, these cells must be capable of suppressing T cell activation. I hypothesized 
that IL-12 can alter the immunosuppressive activity of MDSC leading to potent anti-
tumor effects. These studies confirm a critical difference between MDSC and cells that 
are just Gr-1/CD11b double positive in terms of function, but more importantly, identify a 
new role of IL-12 in immune modulation that is specific to MDSC.  
 
The Gr-1/CD11b double positive cells expanded during tumor growth for both of the 
tumor models studied were found to be functionally suppressive MDSC. Treatment with 
IL-12 was found to alter the suppressive function of these cells by inducing the up-
regulation of markers associated with mature dendritic cells and macrophages. This 
implies a potential new role for IL-12 as an inducer of MDSC cell maturation. According 
to the results of the in vitro studies, tumor-derived MDSC do not up-regulate all markers 
studied. This limitation, however, is not reproduced in the results from the in vivo 
treatments with AdIL-12. There are several key distinctions between the two studies. 
The in vivo studies performed do not isolate the activity of IL-12 to MDSC and do not 
separate interactions between MDSC and other cells. It is probable that the observed 
difference in responsiveness between in vitro and in vivo treatments is due to 
interactions with other immune activators affected by either virus treatment or IL-12, or 
both. The improved response to IL-12 in vivo indicates potential for the potent MDSC 
effects to correlate with anti-tumor activity. 
 
Several key distinctions exist for the MDSC in these studies verses other studies 
performed previously. The MDSC studied in this dissertation do express CD11b, but 
were found to lack F4/80 expression. As mentioned previously, many of the previous 
studies of MDSC in the tumor microenvironment were performed on cells based solely 
on CD11b expression. Studies of cells from the tumor microenvironment that rely solely 
on surface expression of CD11b and either ignore Gr-1 expression or specifically study 
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cells lacking Gr-1 expression do not separate actual MDSC from the CD11b+/Gr-1 
negative macrophages also present in the tumor microenvironment (281-284). The 
studies outlined in this dissertation indicate that the Gr-1/CD11b double positive cells are 
fundamentally different from the tumor-infiltrating macrophages studied previously and 
should be evaluated as a unique population of cells. Although it is possible that some of 
the Gr-1/CD11b double positive cells differentiate upon reaching the tumor 
microenvironment resulting in the down-regulation of Gr-1, the fact that Gr-1/CD11b 
double positive cells remain present in the tumor as well means that no matter what 
changes some of these cells may undergo a population of undifferentiated immature 
MDSC remains. This population of cells should not only be considered as a separate 
population but studied further as there is potential for these cells to suppress T cell 
activation and block anti-tumor immune responses. The studies in this dissertation focus 
on the Gr-1/CD11b double positive cells and identify them as functionally suppressive, 
immature cells expressing at least one of the cytokines expressed by M2 suppressive 
macrophages. Further analysis of the cells is required to completely define the 
differences and similarities between MDSC and other tumor-infiltrating populations such 
as M2 macrophages.  
 
After identifying and beginning to define key differences between MDSC and other 
tumor-infiltrating populations, these studies identify critical effects of treatment with IL-12 
on MDSC activity. In addition to altering the expression of markers indicative of 
maturation, these studies demonstrate that IL-12 alters a few of the internal mechanisms 
of MDSC responsible for conferring their suppressive function. The findings in this 
dissertation demonstrate that IL-12 decreases the expression of Nos2, IFN-γ, and ArgI 
mRNA in MDSC. The presence of all of these factors in the spleen-derived and tumor-
derived Gr-1/CD11b double positive cells supports the findings that the cells from both 
tissue types are suppressive MDSC. Reciprocally, the relatively low expression of these 
factors in naïve spleen-derived Gr-1/CD11b double positive cells supports the findings 
that these cells are not suppressive MDSC. IL-12 is capable of reducing the production 
of each of these factors, demonstrating that the cells have been both phenotypically and 
fundamentally altered and those alterations correlate with the loss in suppressive 
function. The significant difference in overall levels of mRNA expression of Nos2 and 
IFN-γ in Balb/c MDSC for the in vivo study compared to the in vitro study is important to 
consider. This increase in overall expression in vivo could be due to the lack of in vitro 
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culturing for 24 hours. Immediate sorting and RNA extraction from the cells instead of 24 
hour culturing may provide a more accurate analysis of overall mRNA levels. It is 
possible that in vitro culturing has an impact on overall MDSC activity, though further 
experimentation would be required to define what effect (if any) in vitro culturing has on 
these cells. In vitro culture might enhance MDSC activity, but suppressive function is not 
induced by in vitro culture. Since naïve Gr-1/CD11b double positive cells do not 
suppress CD3-mediated T cell activation (Figures 4 C and 4 C), it is likely that the 
suppressive activity is not artificially induced but rather the consequence of true MDSC 
activity. Although suppressive activity conferred by naïve populations was not observed, 
it is possible that the in vitro culturing reduces overall suppressive function in a manner 
that is not observed at the strong 1:1 ratio of MDSC to whole splenocytes. Although 
there was no loss in suppressive function observed in studies of a 1:2 ratio of MDSC to 
whole splenocytes (data not shown), differences may become apparent at a 1:4 or even 
1:8 ratio. 
 
The findings outlined in this dissertation indicate that following treatment with IL-12, 
MDSC are phenotypically altered leading to down-regulation of factors required for 
conferring their suppressive function. A direct correlation between IL-12 signaling and 
down-regulation of any of these factors has not been established. The fact that IFN-γ 
was found to decrease following treatment with IL-12 was particularly interesting since it 
would imply a new role for IL-12 in controlling IFN-γ signaling within certain cell 
populations. Although these data imply a correlation, it is far more likely that treatment 
with IL-12 fundamentally alters the cells resulting in the decreased IFN-γ production 
rather than IL-12 signaling directly turning off IFN-γ production. Further experimentation 
is necessary to define this result and determine specifically how treatment with IL-12 
alters the production of factors necessary for conferring immune suppression. 
 
Although these findings clearly demonstrate both a phenotypic and functional change in 
MDSC induced by IL-12, whether the IL-12-mediated alterations of these cells have 
made them merely no longer suppressive or whether the cells have been activated 
remains to be determined. If the cells have become activated, then not only would they 
no longer suppress anti-tumor immunity, but they would also be capable of promoting an 
anti-tumor immune response. It has been established that MDSC are capable of being 
converted into immunogenic antigen-presenting cells; however, whether IL-12 has the 
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ability to cause this remains unknown (285). The findings that treatment of the functional 
MDSC with IL-12 causes a decrease in IL-10 production and an increase in TNF-α 
production implies that their activity has potentially been switched from blocking immune 
activity to promoting anti-tumor immunity. This appears to be due to an IL-12-induced 
phenotypic change in the cells though it could also be due to direct IL-12-mediated 
signaling. It may be interesting to further define the effect of IL-12 by determining 
whether these cells respond to stimulation by producing M1 or M2 cytokines. 
Challenging the Balb/c-derived MDSC with lipopolysaccharide (LPS) and IFN-γ should 
support the findings of unstimulated cells. LPS stimulated, IL-12-pretreated MDSC 
should respond to immune challenge by up-regulating production of M1 cytokines and/or 
down-regulating the production of M2 cytokines, if they have been converted into a 
population of cells capable of activating immune responses. Further studies will need to 
be performed to identify whether tumor MDSC exhibit additional M2 or M1 macrophage 
characteristics before and after IL-12 treatment in order to fully define the overall activity 
exhibited by MDSC.  
 
Twenty-four hour treatment with AdIL-12 was sufficient to alter the MDSC in vivo but 
defining what role those alterations had on anti-tumor efficacy and long-term immune 
activation is of importance when applying IL-12-based therapies to breast cancer. 
Studies performed on tumor growth and lymphocyte infiltration into the tumor 
microenvironment demonstrated that treatment with AdIL-12 is capable of suppressing 
tumor growth with significant alterations in lymphocyte infiltration. Specifically, AdIL-12 
treated animals exhibited a significant decrease in MDSC and a significant increase in 
tumor-infiltrating CD8+ T lymphocytes. Although significant increases in leukocytes were 
observed, MDSC were found to still be present in the tumors of AdIL-12 treated animals; 
therefore, the activity of the CD8+ T cells needed to be determined. The production of 
intracellular IFN-γ by CD8+ T cells can be used as a marker of activation. Studies 
defining the expression of IFN-γ (as a percentage of CD8+ T cells) performed on the 
CD8+ T cells harvested from AdIL-12 treated animals demonstrated that a larger 
percentage of these cells exhibit IFN-γ expression compared to those from AdLuc 
treated animals. The time point for these studies was weeks after injection with the virus 
implying a long-term effect on immune activation for the therapy. This finding coupled 
with the decrease in MDSC and prolonged overall survival implies that, at least in part, 
IL-12 exerts some of its therapeutic effect through reduction of immune suppression 
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coupled with activation of anti-tumor immunity. Based on the results outlined in this 
dissertation, another role for IL-12 as a modulator of immune suppression has been 
defined as well as a potential target for combination therapies involving IL-12. 
 
Therapies that target immune activation as a means to reject established tumors are 
limited by the presence of cells capable of suppressing immune activity. The ability of T 
cells to be active while in the presence of MDSC and other suppressive populations is 
critical for the immune system to be able to promote an anti-tumor immune response 
(36). The idea that single cytokine treatments can not only promote immune responses 
but also overcome immune suppression is very attractive to researchers as it targets 
multiple aspects of tumor growth and progression. Defining the mechanism of IL-12 
activity on MDSC is essential to understanding the therapeutic applications of IL-12. It is 
well established that IL-12 acts to suppress tumor growth in many tumor models; 
however, why a wide range of responses to IL-12 treatment exists has not yet been fully 
explained. It is clear that IL-12 promotes anti-tumor immune responses but why these 
changes in the tumor microenvironment result in such as dramatically varied responses 
in terms of tumor-growth suppression needs to be explored. This study provides a 
possible explanation for the discrepancy in IL-12-mediated therapeutic response. Since 
IL-12 fundamentally alters the suppressive function of MDSC through potentially 
inducing MDSC maturation then it is possible that differences in MDSC recruitment 
and/or incomplete reversal of MDSC activity by IL-12 can explain why a wide range of 
tumor responses have been observed in many studies. The potential role for IL-12 in 
modulating MDSC recruitment or accumulation should be explored. It is possible that 
treatment with IL-12 alters MDSC as well as tumor-induced cytokine expression long-
term resulting in the decreased MDSC populations observed in these studies. Utilizing 
the enhanced understanding of IL-12 activity on a suppressive cell population obtained 
from these studies could go a long way toward enhancing the therapeutic efficacy of 
combination therapies. For example, treatment with docetaxel was found to alter MDSC 
as well as affect tumor cell growth (286). Combination therapy of docetaxel with IL-12 
may not provide the synergistic or improved therapeutic effects as there is significant 
overlap in activities. Therefore, generating effective combination therapies with 
significant, synergistic anti-tumor activities requires an understanding of all activities 
associated with a given agent prior to combining it with another agent. 
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Treatment of both C3L5 and 4T1 tumor-bearing animals with AdIL-12 resulted not only in 
a suppression of tumor growth but also in an overall reduction in metastasis as 
measured by a reduction in total numbers of lung metastases. The data in this 
dissertation does indicate that the effects of IL-12 on MDSC may be essential to 
permitting T cell activity to reduce metastases. This reduction in metastasis 
demonstrates yet another long-term benefit to treatment with AdIL-12. Whether the 
reduction in metastases is the result of the altered MDSC or a general effect of IL-12 
remains to be determined; however, this finding signals the potential of treatments of this 
type to be useful against advanced disease.   
 
In summary, the findings outlined in this dissertation not only define a previously 
unknown role for IL-12 but also provide a rationale for determining which types of 
combination therapies could have the most therapeutic efficacy. Since IL-12 alone was 
shown to induce significant up-regulation of maturation markers and alter the 
suppressive function of MDSC, combination of it with other MDSC modulators may not 
provide significant improvements over treatment with IL-12 alone. It would instead most 
likely provide optimal therapeutic efficacy to treat tumor-bearing animals with IL-12 in 
combination with agents capable of inducing tumor cell death. Optimal therapeutic 
efficacy would include an increase in complete responders coupled with coinciding 
reductions in metastasis even in cases of advanced disease. Induction of cancer cell 
apoptosis coupled with the IL-12 effects demonstrated here could result in stronger 
suppression of tumor growth and a greater number of animals exhibiting complete tumor 
regression with protection from recurrence.  
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Future Directions 
 
Although these studies have characterized the mechanism through which IL-12 alters 
MDSC and a potential means through which this alteration results in a therapeutic effect, 
several questions remain unanswered. For instance, while this dissertation outlines a 
role for IL-12 in potentially inducing MDSC maturation with accompanying reductions in 
factors responsible for conferring immune regulation, though the actual signaling 
pathway or pathways involved in these changes have not been defined. IL-12 signaling 
through the IL-12R is mediated by both STAT3 and STAT4 while STAT3 is essential to 
MDSC function (202-204, 287-291). Changes in the phosphorylation states and ratio of 
STAT3 to STAT4 would demonstrate that signaling is in fact occurring down the same 
pathway as for traditional IL-12-mediated responses. Disrupting signaling through 
STAT3 is important to consider regarding the findings outlined in this dissertation. Loss 
of STAT3 or changes in STAT3 signaling may be responsible for the down-regulation of 
factors necessary to confer MDSC suppressive function observed in these studies.  
 
In addition to STAT signaling, MDSC function has been shown to occur through MyD88 
signaling (287, 292). Analysis of gene activity for IL-12 responsive genes and 
transcription factors would provide a direct link between the changes observed in this 
dissertation and IL-12 signaling pathways. For example, ArgI production in MDSC has 
been shown to be promoted by cyclooxygenase-2 (COX-2) (130). Alterations in COX-2 
following treatment with IL-12 would establish a direct link between IL-12 signaling and 
the observed reduction in ArgI expression. Many other pathways mediated by the tumor 
microenvironment may also be of interest. For example, new evidence has implicated a 
role for the IL-17 pathway in MDSC mobilization and activity (293, 294). What effect IL-
12 has on this pathway in the tumor microenvironment and regarding MDSC remains to 
be defined. Defining the signaling pathway involved could implicate IL-12 as not only a 
factor that alters MDSC function but also a factor that mediates other MDSC activities. 
 
Treatment of MDSC has been shown to not only reduce suppressive function but to also 
promote a transition of the cells into active antigen-presenting cells (295). The potential 
for IL-12 to not only reduce suppression but also to induce maturation, means that IL-12 
could potentially activate these cells. Increased potential to present antigen is implied by 
the up-regulation of MHCII, but whether these altered cells also have the potential for 
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phagocytic activity or the ability to produce proinflammatory cytokines in response to 
stimuli is of interest in the future. In addition to further characterizing the role of IL-12 in 
terms of the mechanism of its effect on MDSC activity, several specifics regarding IL-12-
mediated changes in both MDSC activity and in the tumor microenvironment remain 
undefined.  
 
The studies in this dissertation demonstrate that cells expressing both Gr-1 and CD11b 
markers are present in the tumor microenvironment and that they are suppressive 
MDSC. This dissertation further characterizes these cells by demonstrating that they are 
a unique cell population lacking expression of the macrophage maturation marker, 
F4/80. Characterizing the complete cytokine and gene expression profile of MDSC 
compared to tumor-infiltrating macrophages should be performed to obtain a complete 
understanding of the activity of these cells in the tumor microenvironment and how they 
differ. Determining the differences between the IL-12-mediated responses of these two 
cell populations is of particular interest in that it could help further define how IL-12 acts 
on immature myeloid cells verses mature myeloid cells. Gaining a better understanding 
of how IL-12 alters MDSC in the tumor and systemically will yield a better understanding 
of how alterations in the tumor microenvironment lead to suppression in tumor growth, 
but also often allow for tumor persistence and regrowth. Defining whether IL-12 has the 
ability to alter MDSC recruitment, for example, will help to define why certain tumors 
respond better than others. If the effects of IL-12 can be better understood, then 
improved therapies can be developed. 
 
The activity of IL-12 as both an immune modulator and an anti-tumor therapeutic agent 
remains of interest for tumor immunologists and will continue to be of interest as long as 
IL-12 continues to show promise as a treatment for cancer. Studies that attempt to 
improve the overall therapeutic efficacy of IL-12 with a reduction in toxic side-effects 
through either combination therapies or improvements in the IL-12 single-cytokine 
therapies could lead to significant implications for treatment of not only breast cancer but 
also other metastatic cancers. The ability to reduce metastasis is an essential ability for 
any treatment aiming to treat advanced carcinomas. As mentioned previously, 
combination of IL-12 with other therapeutic agents must take into account the effects of 
IL-12 single-cytokine therapy in order to determine which agents will provide the best 
therapeutic benefits. Since this dissertation defines a role for IL-12 in potentially inducing 
 95 
 
MDSC maturation, combination therapies involving other agents that induce MDSC 
maturation or differentiation may not have added benefit. For example, combining IL-12 
with ATRA most likely will not enhance the anti-tumor effects of IL-12 as both factors 
affect MDSC in a similar fashion. Combining IL-12 with agents capable of inducing tumor 
cell necrosis or apoptosis will most likely provide optimal therapeutic benefit and should 
be studied.  
 
It is important to note that an additional complication for IL-12-based therapies may exist 
in regards to timing of the therapy. One study determined that blocking MDSC activity 
had to occur early in tumor growth in order to affect overall progression and reduce 
metastatic disease (296). Defining the late vs. early effects of treatment with IL-12 could 
lead to a better understanding of how this treatment as well as alterations in MDSC 
combats disease progression and metastasis. Combination therapies have already been 
shown to reverse tolerance and promote anti-tumor immunity so any studies that attempt 
to determine how IL-12 can be combined to further its effects on these processes are of 
crucial importance to optimizing therapeutic efficacy (297, 298). Better characterization 
of the effects of IL-12-mediated therapy will allow for an enhanced understanding of 
which agents have the most promise for use as combination cancer therapies and how 
alterations in MDSC function factor into promoting the effects of cancer immunotherapy.  
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